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CHAPTER I 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF DISPYRIN 
 
A large amount of the most common metabolites of marine sponges are 
bromopyrrole alkaloids (1).  Sponges of the genus Agelas are found throughout 
the world’s tropical reefs and have provided a wealth of bromopyrrole 
carboxamide containing alkaloids that can be derived biosynthetically from 
oroidin (2).  Examples include the tetracyclic alkaloid (-)-dibromophakelin and the 
tetrasubstituted cyclobutane marine alkaloid (-)-sceptrin (3,4), Figure 1.  In 2007, 
Crews and co-workers reported on the discovery of a new bromopyrrole alkaloid, 
dispyrin 1, from the Carribean sponge Agelas dispar, Figure 1 (5). 
 
 
Figure 1.  Examples of marine natural products from sponges Agelas. 
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Unlike many laboratories that rely on bio-fractionation, triaging natural 
product extracts or sponge/soil samples for antibacterial or anticancer activities, 
the Crews laboratory focused on discovering compounds with unique molecular 
architectures.  Dispyrin is novel in that it contains a distinct bromopyrrole 
tyramine motif that has no precedent in marine natural products research.  Crews 
also reported that unlike all bromopyrrole carboxamide alkaloids discovered from 
Agelas thus far, dispyrin has an independent biosynthetic pathway and is not 
biosynthetically derived from oroidin (5).  Crews and co-workers did not ascribe 
any biological activity for dispyrin 1, since our laboratory is interested in new 
biologically active compounds we initiated a program to synthesize dispyrin 1 and 
elucidate the molecular target(s) of this unique natural product with a 
bromopyrrole carboxamide alkaloid. 
 
 
 
Figure 2. Structure of the dispyrin 1, a bromopyrrole alkaloid from Agelas dispar. 
 
As outlined in Scheme 1, our retrosynthetic analysis of dispyrin 1 
envisaged an amide coupling between 4-bromo-2-carboxypyrrole 2 and 3-bromo-
 3 
4-hydroxyphenethylamine 3, followed by an alkylation or Mitsunobu reaction with 
N,N-dimethyl-3-chloropropyl amine or N,N-dimethyl-3-hydroxypropyl amine 4, 
respectively.  This expedited route should allow for the synthesis of gram 
quantities of dispyrin 1 to facilitate biological evaluation as well as an opportunity 
to readily prepare libraries of unnatural analogues (5). 
 
 
Scheme 1.  Retrosynthetic analysis of dispyrin 1. 
 
As shown in Scheme 2, our synthesis began with commercially available 
acid 2, which was coupled to 3-bromo-4-methoxyphenethylamine 5 to provide 6 
in 93% yield.   Subsequent deprotection of the methyl ether with BBr3 afforded 7 
in 92% yield.  Multiple alkylation protocols were attempted, as well as Mitsunobu 
protocols, but all failed to deliver dispyrin 1 in reasonable yields.  Ultimately, 
 4 
phenol 7 was successfully alkylated with N,N-dimethyl-3-chloropropyl amine 4, 
under a microwave-assisted protocol at 160oC for 20 minutes, to deliver dispyrin 
1 in 80% isolated yield.  Thus, the first total synthesis of dispyrin 1 was 
completed on a one-gram scale in three synthetic steps with an overall yield of 
68.4% (7).  In the original disclosure by Crews et al., spectroscopic data were 
reported for what was depicted as the free base of dispyrin 1.  The spectroscopic 
data (1H, 13C NMR and MS) we obtained for synthetic 1 were not in complete 
accordance with that reported for dispyrin 1 by Crews and co-workers (5).
 
  
 
Scheme 2.  Synthesis of dispyrin 1.   
 
We rationalized that the discrepancies observed could arise if the 
spectroscopic data reported for 1 were of the corresponding protonated salt form 
 5 
of the distal dimethylamino moiety.  To evaluate this possibility, we synthesized 
the corresponding HCl salt of our synthetic dispyrin 1.  As shown in Scheme 3, 
dispyrin 1 was dissolved in MeOH, and HCl gas was bubbled through the 
solution for 10 minutes.  The reaction solution was concentrated and washed 
with dry Et2O.  The resulting white solid, the HCl salt of dispyrin 9, provided 
spectroscopic data (1H, 13C NMR and MS) in complete accordance with that 
reported for dispyrin 1 by Crews and co-workers; thus, the original report of 
natural dispyrin 1 characterized a protonated salt form, such as 9, and not the 
free-base 1 (5). 
 
  The NMR spectroscopic comparison is summarized in Table 1. 
 
Scheme 3.  Synthesis of the HCl salt of dispyrin 9. 
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Table 1.  NMR comparison of Dispyrin reported by Crews et al. and synthetic 
Dispyrin x HCl, 9. 
 
With a large quantity of dispyrin 1 in hand, we embarked on the study to 
identify potential molecular target(s) for dispyrin 1.  With thousands of discrete 
molecular targets known, it was a challenge to develop a plan to evaluate 
dispyrin 1 against all potential biological targets; moreover, unlike traditional 
natural products research, we did not want to solely focus on antibacterial and 
 7 
anticancer activity.  After careful consideration, we pursued multiple screening 
avenues.  In the pharmaceutical industry, medicinal chemists evaluate late stage 
preclinical candidates against large panels of discrete molecular targets in an 
attempt to identify ancillary pharmacology and potential problems.  In a paradigm 
change, we took advantage of this approach, but employed the power of these 
large panels of G protein-coupled receptors (GPCRs), ion channels, transporters 
and kinases to potentially elucidate a molecular target(s) for dispyrin 1.  Utilizing 
panels of radioligand binding assays from several companies, dispyrin 1 was 
evaluated against >200 discrete molecular targets over the course of two 
months.  The MDS Pharma Services panel identified multiple activities for 
dispyrin 1 (8).  In the initial screen at a single 10 µM concentration, dispyrin 1, 
was found to provide modest inhibition (50-60% at 10 µM) of calcium (L-type) 
and potassium (hERG) ion channels, but none with significant activity after full 
concentration-response-curves were obtained (no Kis or IC50
Importantly, the MDS panel identified four G protein-coupled receptors 
(adrenergic α
s <10 µM) (7,8).  
1D, adrenergic α2A, H2 and H3 receptors) against which 1 showed 
promising therapeutic potential (8-10).  Amongst the adrenergic family of GPCRs, 
the α1D and α2A subtypes are well-documented targets for hypertension as they 
contribute to smooth muscle contraction and neural baroreflex control of blood 
pressure (11-12).  A number of H2 receptor antagonists are on the market for the 
treatment of peptic ulcer disease, and the H3 receptor is a well validated target 
for a number of CNS pathologies including depression, schizophrenia, ADHD, 
dementia and sleep disorders (13,14).  As shown in Table 2, dispyrin 1 displayed 
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significant inhibition in a single point screen at 10 µM against these four GPCRs, 
which justified obtaining full dose-response curves.  Dispyrin 1 showed 
nanomolar binding and inhibition of both the adrenergic α1∆ receptor (Ki = 275 
nM, IC50 = 560 nM) and the α2Α receptor (Ki = 69 nM, IC50 = 180 nM), while 
affording low micromolar binding and inhibition of both the H2 receptor (Ki = 1.02 
M, IC50 = 1.25 µM) and the   receptor (Ki = 1.04 µM, IC50
 
 = 2.35 µM) (7,8).  
Thus, dispyrin 1 represents a new chemotype and a potential novel lead 
compound for these therapeutically important molecular targets, and a rare 
example of a marine natural product as a ligand for such GPCRs. 
 
Table 2.  Biological evaluation of dispyrin 1. 
 
In order to evaluate functional activity, dispyrin 1 was also placed on the 
screening deck of the Vanderbilt Screening Center for GPCRs, Ion Channels and 
Transporters, a member of the Molecular Library Screening Center Network 
which employs cell-based functional assays (15).  Thus far, dispyrin 1 has yet to 
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be identified as a hit, but it will remain on the Vanderbilt screening deck and will 
be evaluated in ~20 assays/year. 
In summary thus far, we have completed the first total synthesis of 
dispyrin 1 on a 1 gram scale, demonstrated that the spectroscopic data reported 
for the natural product 1 were that of a protonated salt form, such as 9 and not 
the free base (as reported), and that dispyrin is a potent ligand for therapeutically 
important GPCRs (the adrenergic α1D, adrenergic α2A, H2 and H3
 Based on these data, we initiated a natural product guided synthesis 
effort, employing iterative parallel synthesis (18) for molecular editing, aimed at 
improving H
 receptors). 
3
 
 inhibition and binding; moreover, we wanted to validate the marine 
natural product dispyrin 1 as a viable lead molecule due to the novel scaffold 
providing intellectual property in extremely crowded chemical space. 
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Scheme 4.  First-Generation Library Synthesis. 
 
The first generation 25-member library was based on a 5 x 5 two-
dimensional matrix design wherein the core was held constant and the amide R1 
and aminoalkyl moieties R2 varied, Scheme 4.   The library synthesis began with 
a simple DIC amide coupling employing commercially available 3-bromo-4-
methoxyphenylethylamine 5 with one of five heterocyclic carboxylic acids 
designated R1.  These five scaffolds were then treated with BBr3 to remove the 
methyl ether generating the free phenols 12.  Each of the five phenols 12 was 
then alklyated with one of five aminoalkyl chlorides to install R2 under microwave-
assisted conditions to afford 25 unnatural dispyrin analogs 13 which were the 
purified to >98% by mass directed HPLC (18).   
 11 
This first generation library was highly informative.  In general, all R1s and 
R2s afforded modestly potent (Kis and IC50s in the low micromolar range) H3 
antagonists.  Potent H3 antagonists (Kis < 200 nM, IC50s < 430 nM) resulted for 
all of the heterocyclic amides R1 in combination with the ethyl pyrrolidinyl R2 (13c, 
13h, 13m, 13r and 13w).  In contrast, the ethyl morpholino congeners (13d, 13i, 
13n, 13s and 13x) were uniformly weak (Kis > 12 µM, IC50s > 29 µM).   The most 
potent H3 antagonist from the first generation library was 13r (R1 = 4-bromo-
thiophene, R2 = ethyl pyrrolidine) with a Ki of 80 nM and an IC50 of 180 nM – a 
13-fold improvement over the parent natural product dispyrin 1 (IC50 = 2.35 µM, 
Ki = 1.04 µM).  Based on these data, the next library maintained R1 = 4-bromo-
thiophene and surveyed functionalized pyrrolidines at R2
 
.  
 12 
 
Table 3.  Structures and activities of dispyrin analogs 13. 
 
 
 13 
 
Scheme 5.  Second Generation Library Synthesis. 
 
Following Scheme 4, a large quantity of 14 was prepared.  Then, the 
phenol was alkylated with 2-bromo-1,1-dimethoxy ethane 15 to provide 16, which 
was then converted to the corresponding aldehyde 17 by treatment with tosylic 
acid via microwave irradiation.  Finally, reductive amination employing a 
functionalized pyrrolidine and MP-B(OAc)3H provided analogs 18, which were 
purified to >98% by mass-directed preparative HPLC (18).  As shown in Table 4, 
analogs 18 were weaker H3 antagonists than 13r, and there was no evidence of 
enantioselective inhibition (18a vs. 18b).  Incorporation of β-fluorine atoms such 
as in 18c and 18d, which lower the pKa on the pyrrolidine nitrogen from 11 to 9, 
afforded diminished H3 inhibition (13). 
 14 
 
Table 4.  Structures and activities of dispyrin pyrrolidine analogs 18. 
 
We then prepared two singleton compounds following the synthetic route 
depicted in Scheme 4 with the appropriate substitutions, wherein the bromine in 
13r was replaced with a chlorine 19 and a truncated version 20, Figure 2.   A 2-
fold diminution in potency was noted for 19, relative to 13r, and the truncated 
benzyl version lost over 13-fold compared to 13r; however, this highlighted that 
the heavy bromine atom was not required for H3
 
 inhibition. 
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Figure 3.  Chlorinated version and chlorinated truncated version of 
bromothiophene analogues, 14r.  
 
The final library iteration was directed at surveying a wider range of 
alternative amides (heterocycles and functionalized aromatic moieties) while 
holding the preferred ethyl pyrrolidine ether and bromotyramine core constant.  
The synthesis began with 5 and conversion to the phthalimide congener 21 using 
MAOS.   Standard BBr3
 
 deprotection provided 22, which was alkylated with 
chloroethyl pyrrolidine 23 to deliver 24.  Hydrolysis of the phthalimide with 
hydrazine afforded 25, followed by amide coupling with a diverse collection of 
aryl and heteroaryl carboxylic acids generated library 26 shown in Scheme 6, 
these library members were purified to >98% purity by mass-directed preparative 
HPLC (18). 
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Scheme 6.  Third-generation library synthesis. 
 
This third generation library was uniformly active, providing H3 antagonists 
in the sub-micromolar range, Table 5.  Six-member heterocycles, such as 
pyridine 26a, were active, as were aryl amides with halogens (Cl and Br) or 
trifluoromethyl groups in the 3-position (26f-26h).  Five-member heterocycles 
(26b-26e) proved optimal, with a 5-oxazole 26b (Ki = 32 nM, IC50 = 83 nM) and 
2-thiazole 26d (Ki = 32 nM, IC50 = 72 nM) affording the most potent H3 
antagonists of the unnatural dispyrin analogs.  For example, 26d improved the 
H3 Ki and IC50 ~33-fold over the natural product dispyrin, and required only three 
 17 
iterations of molecular editing and 40 analogs.  Moreover, as dispyrin 1 
represented a novel chemotype, we were able to obtain composition of matter 
patents for the dispyrin analogs as H3
 
 antagonists within an incredibly crowded 
intellectual property landscape (20).  This effort highlights the value of employing 
natural products as leads for therapeutically relevant targets. 
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Table 5.  Structures and activities of third-generation dispyrin acid analogs 26. 
 
During the course of the total synthesis of dispyrin we have completed the 
first total synthesis of dispyrin 1 on a 1 g scale and demonstrated that the 
 19 
spectroscopic data reported for the natural product 1 were that of a protonated 
salt form, such as 2, and not the free base (as reported), and that dispyrin is a 
potent ligand for therapeutically important GPCRs (the adrenergic α1D, 
adrenergic α2Α, H2, and H3
 
 receptors) Figure 4. 
 
Figure 4.  Structure of dispyrin 1 and the protonated form 9. 
 
We employed a natural product guided synthesis effort in molecular 
editing, employing itertative parallel synthesis, quickly optimized the weak H3 
antagonsim of the marine natural product dispyrin 1 over 30-fold to afford 
unnatural analogs 26d and 26e with low nanomolar potency and binding, Figure 
5. 
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Figure 5.  Summary of structures and binding potencies of dispyrin 1 and the two 
best library compounds 26d and 26e. 
 
By employing a novel natural product scaffold for lead optimization, we 
were able to establish an intellectual property position in an incredibly crowded 
intellectual property landscape.  Although the role of natural products drug 
discovery efforts within the pharmaceutical industry is being significantly reduced, 
despite overwhelming success, the biological activity of dispyrin and its analogs 
argue further that natural products are viable drug leads and have the potential to 
offer patenting advantages. 
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Experimental Procedures for the Synthesis of Dispyrin- 
 
4-bromo-N-(3-bromo-4-methoxyphenethyl)-1H-pyrrole-2-carboxamide 6:  
To a stirred solution of acid 2 (1.00 g, 5.3 mmol), HOBt (1.50 g, 11.0 mmol), and 
amine 5 (1.21 g, 5.3 mmol) in 9:1 CH2Cl2:DIEA at 25 oC was added DIC (1.33 g, 
10.6 mmol) and the mixture was stirred overnight.  After quenching with 250 mL 
water, the reaction was added to a 500 mL separatory funnel and extracted 3 x 
200 mL CH2Cl2.  The organic layers were combined, and washed with 500 mL 
saturated aqueous brine solution.  The organic layer was dried over MgSO4, and 
concentrated in vacuo to yield the crude coupled product.  The crude material 
was then subjected to flash chromatography (EtOAc:Hexanes 1:1) to give pure 6 
as a white solid (1.98 g, 4.9 mmol, 93 % yield).  1H NMR (400 MHz, DMSO-d6) δ 
8.13 (t, J = 5.6 Hz, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.17 (dd, J = 1.6, 8.4 Hz, 1H), 
7.00 (d, J = 8.4 Hz, 1H), 6.96 (m, 1H), 6.82 (s, 1H), 3.80 (s, 3H), 3.40 (q, J = 6.8 
Hz, 2H), 2.74 (t, J = 7.2 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 159.5, 153.7, 
133.3, 132.9, 129.1, 126.9, 121.1, 112.5, 111.3, 110.4, 94.9, 56.1, 40.1, 33.8.  
HRMS (Q-TOF): m/z calc for C14H14Br2N2O2 [M + H]:  400.9500; found 
400.9517. 
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4-bromo-N-(3-bromo-4-hydroxyphenethyl)-1H-pyrrole-2-carboxamide 7:  
To a stirred solution of coupled material 6 (1.00 g, 2.5 mmol) in anhydrous 
CH2Cl2 under argon at -78 oC was added BBr3 (10 mL, 10 mmol, 1.0 M solution 
in CH2Cl2) over 20 minutes.  The solution was stirred at -78 oC for 30 minutes 
and then allowed to warm to 25 oC for 1.5 hours.  The reaction was slowly 
quenched with saturated aqueous NaHCO3 until slightly basic by pH paper.  This 
solution was added to a 1 L separatory funnel containing 500 mL water and 
extracted with 3 x 300 mL CH2Cl2.  The combined organic layers were washed 
with 500 mL saturated aqueous brine solution.  The organic layer was dried over 
MgSO4, and concentrated in vacuo to yield the deprotected product 7 (0.89 g, 
2.3 mmol, 92 % yield).  This material was used without further purification.  1H 
NMR (400 MHz, DMSO-d6) δ 9.98 (br s, 1H) 8.11 (t, J = 5.2 Hz, 1H), 7.33 (d, J = 
1.6 Hz, 1H), 7.02 (dd, J = 2.0, 8.4 Hz, 1H), 6.95 (m, 1H), 6.85 (d, J = 8.0 Hz, 1H), 
6.80 (d, J = 2.0 Hz, 1H), 3.37 (m, 2H), 2.68 (t, J = 6.8 Hz, 2H). 13C NMR (100 
MHz, DMSO-d6) δ 159.5, 152.3, 132.7, 131.6, 128.9, 126.9, 121.0, 116.2, 111.3, 
109.0, 94.9, 40.2, 33.9. HRMS (Q-TOF): m/z calc for C13H12Br2N2O2 [M + H]:  
386.9344; found 386.9359. 
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(4-bromo-N-(3-bromo-4-(3-(dimethylamino)propoxy)phenethyl)-1H-pyrrole-
2-carboxamide), Dispyrin 1:   
In a 5 mL microwave vial containing 7 (100 mg, 0.26 mmol), amine 16 (49 mg, 
0.31 mmol), KI (129 mg, 0.78 mmol), and Cs2CO3 (254 mg, 0.78 mmol) was 
added anhydrous DMF, 4 mL.  This was heated under microwave conditions at 
160 oC for 20 minutes.  The reaction was filtered, concentrated in vacuo and 
purified via mass directed HPLC to obtain pure dispyrin as the TFA salt.  This 
material was dissolved in a minimal amount of MeOH, and added to a 12 mL 
SCX solid phase extractor column, which was washed with 2 column volumes 
MeOH.  The material was removed from the column by eluting with 2 column 
volumes 2 M NH3 in MeOH.  This was again concentrated in vacuo to obtain 
pure dispyrin 1 as the free base (98 mg, 0.21 mmol, 80 % yield). 1H NMR (400 
MHz, MeOH-d4) δ 7.42 (d, J = 2.0 Hz, 1H), 7.14 (dd, J = 2.0, 8.4 Hz, 1H), 6.93 
(d, J = 8.4 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.70 (d, J = 1.6 Hz, 1H), 5.48 (s, 
1H), 4.05 (t, J = 6.0 Hz, 2H), 3.47 (t, J = 7.6 Hz, 2H), 2.78 (t, J = 7.2 Hz, 2H), 
2.61 (t, J = 7.6 Hz, 2H), 2.30 (s, 6H), 1.99 (m, 2H).  13C NMR (100 MHz, MeOH-
d4) δ 162.5, 155.2, 134.5, 130.1, 127.6, 122.7, 114.6, 113.1, 112.9, 97.4, 68.2, 
57.4, 49.0, 45.4, 42.0, 35.6, 28.0.  HRMS (Q-TOF): m/z calc for C18H23Br2N3O2 
[M + H]:  472.0235; found 472.0243.  
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(4-bromo-N-(3-bromo-4-(3-(dimethylamino)propoxy)phenethyl)-1H-pyrrole-
2-carboxamide) Hydrochloride, 9:   
Dispyrin (1) (400 mg, 845 mmol) was dissolved in MeOH (20 mL).  HCl gas was 
bubbled slowly through the solution for 10 min.  The solvent was removed in situ 
and washed with anhydrous ether (3 x 20 mL) too afford Dispyrin HCl as a white 
solid (420 mg, 98 %).  1H-nmr (400 MHz, MeOH-d4)  7.45 (d, J = 2.0 Hz, 1H), 
7.17 (dd, J = 2.0, 8.0 Hz, 1H), 6.97 (d, J = 8.0 Hz, 1H), 6.90 (d, J = 1.6 Hz, 1H), 
6.72 (d, J = 1.6 Hz, 1H), 4.15 (t, J = 5.6 Hz, 2H), 3.48 (t, J = 7.6 Hz, 2H), 3.39 (t, 
J = 7.6 Hz, 2H), 2.96 (s, 6H), 2.80 (t, J = 7.2 Hz, 2H), 2.25 (m, 2H).  13C-nmr (100 
MHz, MeOH-d4)  162.6, 154.7, 135.3, 134.6, 130.4, 127.6, 122.8, 114.8, 113.3, 
112.9, 97.5, 67.5, 57.2, 43.8, 42.0, 35.6, 25.7.  HRMS (Q-TOF): m/z calc for 
C18H24Br2N3O2 [M + H+
 
]:  472.0234; found 472.0235. 
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General Synthetic Scheme 1. 
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General Coupling Procedure for Library Synthesis:   
To a stirred solution of acid R1COOH (1 equivalent), HOBt (2.1 equivalents), and 
amine I-1 (1 equivalent) in 9:1 CH2Cl2:DIEA at 25 oC was added DIC (2 
equivalents) and the mixture was stirred overnight.  After quenching with water, 
the reaction was added to a separatory funnel and washed 3x with CH2Cl2.  The 
organic layers were combined, and washed with saturated aqueous brine 
solution.  The organic layer was dried over MgSO4, and concentrated in vacuo to 
yield I-2.  The crude material was then subjected to flash chromatography to give 
pure I-2 as a white solid (79-93 % yield). 
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N-(3-bromo-4-methoxyphenethyl)-1H-pyrrole-2-carboxamide 11f:  
1H NMR (400 MHz, DMSO-d6) δ 9.31 (br s, 1H), 7.42 (d, J = 2.0, 1H), 7.12 (dd, J 
= 2.0, 8.4 Hz, 1H), 6.92 (m, 1H), 6.84 (d, J = 8.4 Hz, 1H), 6.44 (s, 1H), 6.22 (m, 
1H), 5.85 (m, 1H), 3.89 (s, 3H), 3.63 (q, J = 6.8 Hz, 2H), 2.82 (t, J = 7.2 Hz, 2H).  
13C NMR (100 MHz, DMSO-d6) δ 161.4, 154.5, 133.4, 231.4, 128.7, 125.7, 
121.8, 112.0, 111.6, 109.0, 77.3, 76.9, 76.7, 56.2, 40.5, 34.7.  HRMS (Q-TOF): 
m/z calc for C14H15BrN2O2
 
 [M + H]:  323.0395; found 323.0408.  84.7 % yield. 
 
4-bromo-N-(3-bromo-4-methoxyphenethyl)thiophene-2-carboxamide 11p:  
1H NMR (400 MHz, DMSO-d6) δ 7.41 (d, J = 2.0 Hz, 1H), 7.37 (s, 1H), 7.27 (s, 
1H), 7.12 (dd, J = 2.0, 8.4 Hz, 1H), 6.86 (d, J = 8.0 Hz, 1H), 5.93 (m, 1H), 3.89 (s, 
3H), 3.63 (q, J = 6.8 Hz, 2H), 2.84 (t, J = 7.2 Hz, 2H), 2.17 (s, 1H).  13C NMR 
(100 MHz, DMSO-d6) δ 159.8, 153.8, 141.1, 133.0, 132.9, 129.7, 129.1, 128.5, 
 31 
112.5, 110.3, 108.6, 56.1, 40.7, 33.5. HRMS (Q-TOF): m/z calc for 
C14H13Br2NO2
 
S [M + H]:  417.9112; found 417.9120.  79 % yield. 
5-bromo-N-(3-bromo-4-methoxyphenethyl)furan-2-carboxamide 11u:  
1H NMR (400 MHz, DMSO-d6) δ 7.42 (d, J = 2.0 Hz, 1H), 7.13 (dd, J = 2.0, 8.0 
Hz, 1H), 7.06 (d, J = 3.6 Hz, 1H), 6.85 (d, J = 8.4 Hz, 1H), 6.43 (d, J = 3.2 Hz, 
1H), 6.32 (br s, 1H), 3.88 (s, 3H), 3.62 (m, 2H), 2.83 (t, J = 7.2 Hz, 2H).  13C NMR 
(100 MHz, DMSO-d6) δ 156.6, 153.8, 149.7, 133.0, 132.9, 129.1, 124.2, 115.6, 
113.9, 112.5, 110.3, 56.1, 40.0, 33.6.  HRMS (Q-TOF): m/z calc for 
C14H13Br2NO3
 
 [M + H]:  401.9340; found 401.9350.  91 % yield. 
 
N-(3-bromo-4-methoxyphenethyl)-1-methyl-1H-pyrrole-2-carboxamide 11k:  
1H NMR(400 MHz, DMSO-d6) δ 8.01 (t, J = 5.2 Hz, 1H), 7.43 (d, J = 1.2 Hz, 1H), 
7.18 (d, J = 6.8 Hz, 1H), 7.01 (d, J = 8.4 Hz, 1H), 6.86 (s, 1H), 6.70 (d, J = 2.0 
Hz, 1H), 5.98 (t, J = 3.2 Hz, 1H), 3.81 (d, J = 3.2 Hz, 6H), 3.36 (m, 2H). 13C NMR 
(100 MHz, DMSO-d6) δ 161.3, 153.7, 133.45, 132.9, 129.1, 127.5, 125.7, 112.5, 
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112.5, 111.9, 110.3, 106.5, 56.1, 40.0, 36.0, 33.9.  HRMS (Q-TOF): m/z calc for 
C15H17BrN2O2
 
 [M + H]:  337.0552; found 337.0563.  82 % yield. 
General Deprotection Procedure for Library Synthesis:   
To a stirred solution of coupled material I-2 (1 equivalent) in anhydrous CH2Cl2 
under argon at -78 oC was added BBr3 (4 equivalents of 1.0 M solution in 
CH2Cl2) over 20 minutes.  The solution was stirred at -78 oC for 30 minutes and 
then allowed to warm to 25 oC for 1.5 hours.  The reaction was slowly quenched 
with saturated aqueous NaHCO3 until slightly basic by pH paper.  This solution 
was added to a separatory funnel containing water and extracted 3x with CH2Cl2.  
The combined organic layers were washed with saturated aqueous brine 
solution.  The organic layer was dried over MgSO4
 
, and concentrated in vacuo to 
yield the deprotected product I-3 (82-92 % yield).  This material was used without 
further purification. 
 
N-(3-bromo-4-hydroxyphenethyl)-1H-pyrrole-2-carboxamide 12f:  
1H NMR (400 MHz, DMSO-d6) δ 11.36 (s, 1H), 7.99 (br s, 1H), 7.32, (d, J = 2.0 
Hz, 1H), 7.10 (dd, J = 2.0, 8.0 Hz, 1H), 6.84 (d, J = 8.4 Hz, 1H), 6.81 (br s, 1H), 
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6.70 (br s, 1H), 6.04 (m, 1H), 3.34 (q, J = 6.8 Hz, 2H), 2.68 (t, J = 7.2 Hz, 2H).  
13C NMR (100 MHz, DMSO-d6) δ 160.5, 152.2, 132.7, 131.8, 128.8, 126.3, 
121.1, 116.2, 109.6, 108.9, 108.4, 40.2, 39.9, 39.7, 39.5, 39.3, 39.1, 34.0.  
HRMS (Q-TOF): m/z calc for C13H13BrN2O2
 
 [M + H]:  309.0239; found 309.0241.  
92 % yield. 
 
4-bromo-N-(3-bromo-4-hydroxyphenethyl)thiophene-2-carboxamide 12p:  
1H NMR (400 MHz, DMSO-d6) δ 9.99 (br s, 1H) 8.62 (t, J = 5.6 Hz, 1H), 7.87 (d, 
J = 1.2 Hz, 1H), 7.73 (d, J = 1.2 Hz, 1H), 7.32 (d, J = 1.6 Hz, 1H), 7.00 (dd, J = 
2.0, 8.4 Hz, 1H), 6.84 (d, J = 8.4, 1H), 3.38 (q, J = 6.8 Hz, 3H), 2.69 (t, J = 7.2, 
2H).  13C NMR (100 MHz, DMSO-d6) δ 159.7, 152.3, 141.2, 132.7, 131.4, 129.7, 
128.9, 128.5, 116.2, 109.0, 108.1, 40.8, 33.58.  HRMS (Q-TOF): m/z calc for C-
13H11Br2NO2
 
S [M + H]:  403.8955; found 403.8967.  82.2 % yield. 
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5-bromo-N-(3-bromo-4-hydroxyphenethyl)furan-2-carboxamide 12u:  
1H NMR (400 MHz, DMSO-d6) δ 9.98 (br s, 1H), 8.44 (t, J = 5.6 Hz, 1H), 7.30 (d, 
J = 1.6 Hz, 1H), 7.08 (d, J = 3.6 Hz, 1H), 7.00 (dd, J = 2.0, 8.4 Hz, 1H), 6.84 (d, J 
= 8.4 Hz, 1H), 6.72 (d, J = 3.6 Hz, 1H), 3.35 (q, J = 6.8 Hz, 2H), 2.68 (t, J = 7.2 
Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 156.4, 152.1, 149.6, 132.5, 131.2, 
128.7, 124.0, 116.0, 115.4, 113.7, 108.8, 39.9, 33.5.  HRMS (Q-TOF): m/z calc 
for C13H11Br2NO3
 
 [M + H]:  387.9184; found 387.9198.  84.2 % yield. 
 
N-(3-bromo-4-hydroxyphenethyl)-1-methyl-1H-pyrrole-2-carboxamide 12k:  
1H NMR (400 MHz, DMSO-d6) δ 9.97 (s, 1H), 7.98 (t, J = 5.6 Hz, 1H), 7.31 (d, J 
= 1.6 Hz, 1H), 7.00 (dd, J = 1.6, 8.0 Hz, 1H), 6.85 (m, 2H), 6.68 (m, 1H), 5.97 (m, 
1H), 3.79 (s, 3H), 3.31 (q, J = 7.6 Hz, 2H), 2.69 (t, J = 7.6 Hz, 2H).  13C NMR 
(100 MHz, DMSO-d6) δ 161.7, 152.6, 133.1, 132.2, 129.3, 127.8, 126.1, 116.6, 
112.3, 109.4, 106.9, 40.6, 36.4, 34.4.  HRMS (Q-TOF): m/z calc for 
C14H15BrN2O2
 
 [M + H]:  323.0395; found 323.0398.  88.7 % yield. 
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General Alkylation Procedure for Library Synthesis:  
In a 5 mL microwave vial containing I-3 (1 equivalent), alkyl halide (1.2 
equivalents), KI (3 equivalents), and Cs2CO3 (3 equivalents) was added 
anhydrous DMF, 4 mL.  This was heated under microwave conditions at 160 o
 
C 
for 20-60 minutes.  The reaction was filtered, concentrated in vacuo and purified 
via mass directed HPLC to obtain pure I-4 as the TFA salt (15-85% yield). 
 
4-bromo-N-(3-bromo-4-(2-(dimethylamino)ethoxy)phenethyl)-1H-pyrrole-2-
carboxamide 13b: 
1H NMR (400 MHz, DMSO-d6) δ 9.98 (br s, 1H), 8.14 (t, J = 4 Hz, 1H), 7.50 (d, J 
= 2.0 Hz, 1H), 7.22 (dd, J = 1.6, 8.4 Hz, 1H), 7.1 (d, J = 8.4 Hz, 1H), 6.96 (m, 
1H), 6.81 (m,1H), 4.37 (t, J = 4.8 Hz, 2H), 3.55 (m, 2H), 3.41 (q, J = 6.4 Hz, 2H), 
2.92 (s, 6H), 2.77 (m, 2H).  13C NMR (100 MHz, DMSO-d6) δ 159.9, 152.6, 
134.5, 133.3, 129.4, 127.9, 121.2, 114.0, 111.4, 110.8, 95.0, 63.1, 55.6, 43.5, 
40.4, 33.9.  HRMS (Q-TOF): m/z calc for C17H21Br2N3O2 [M + H]:  458.0079; 
found 458.0076. 
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4-bromo-N-(3-bromo-4-(2-(pyrrolidin-1-yl)ethoxy)phenethyl)-1H-pyrrole-2-
carboxamide 13c: 
1H NMR (400 MHz, DMSO-d6) δ 10.06 (br s, 1H), 8.14 (t, J = 5.2 Hz, 1H), 7.50 
(d, J = 2.0 Hz, 1H), 7.22 (dd, J = 1.6, 8.4 Hz, 1H), 7.09 (d, J = 8.4 Hz, 1H), 6.95 
(m, 1H), 6.81 (m, 1H), 4.34 (t, J = 4.4 Hz, 2H), 3.64 (m, 4H), 3.41 (q, J = 6.4 Hz, 
2H), 3.18 (m, 2H), 2.76 (t, J = 6.8 Hz, 2H), 2.04 (m, 2H), 1.87 (m, 2H).  13C NMR 
(100 MHz, DMSO-d6) δ 159.5, 152.3, 134.4, 133.1, 129.2, 126.9, 121.1, 113.8, 
111.3, 110.6, 94.8, 64.8, 54.4, 52.8, 40.0, 33.7, 22.5.  HRMS (Q-TOF): m/z calc 
for C19H23Br2N3O2
 
 [M + H]:  484.0235; found 484.0226. 
 
4-bromo-N-(3-bromo-4-(2-morpholinoethoxy)phenethyl)-1H-pyrrole-2-
carboxamide 13d: 
1H-nmr (400 MHz, DMSO-d6) δ 10.30 (br s, 1H), 8.14 (t, J = 5.6 Hz, 1H), 7.50 (d, 
J = 1.6 Hz, 1H), 7.22 (dd, J = 1.6, 8.4 Hz, 1H), 7.10 (d, J = 8.4 Hz, 1H), 6.95 (m, 
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1H), 6.80 (m, 1H), 4.40 (t, J = 4.8 Hz, 2H), 3.98 (m, 2H), 3.70 (m, 2H), 3.59 (m, 
2H) 3.41 (q, J = 6.8 Hz, 2H), 3.29 (m, 2H), 2.76 (t, J = 7.2 Hz, 2H).  13C-nmr (100 
MHz, DMSO-d6) δ 159.5, 152.2, 134.4, 133.1, 129.2, 128.7, 121.1, 113.9, 111.3, 
110.7, 94.84, 63.9, 63.4, 55.0, 52.2, 40.0, 33.8.  HRMS (Q-TOF): m/z calc for C-
19H23Br2N3O3 [M + H+
 
]:  500.0184; found 500.0161. 
 
4-bromo-N-(3-bromo-4-((1-methylpiperidin-3-yl)methoxy)phenethyl)-1H-
pyrrole-2-carboxamide 13e:  
1H NMR (400 MHz, DMSO-d6) δ 9.71 (br s, 1H), 8.14 (t, J = 5.2 Hz, 1H), 7.46 (d, 
J = 2.0 Hz, 1H), 7.18 (dd, J = 1.6, 8.4 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 6.95 (m, 
1H), 6.81 (m, 1H), 3.99 (m, 1H), 3.89 (m, 1H), 3.51 (m, 1H), 3.40 (m, 3H), 2.80 
(m, 4H), 2.74 (t, J = 6.8 Hz, 2H), 2.25 (m, 1H), 1.88 (m, 2H), 1.68 (m, 2H), 1.30 
(m, 1H). 13C NMR (100 MHz, DMSO-d6) δ 159.5, 152.7, 133.9, 132.9, 129.2, 
126.9, 121.1, 113.9, 111.3, 110.9, 94.8, 70.3, 55.7, 53.7, 43.1, 40.0, 34.3, 33.7, 
23.9, 22.1.  HRMS (Q-TOF): m/z calc for C20H25Br2N3O2
 
 [M + H]:  498.0392; 
found 498.0407. 
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N-(3-bromo-4-(3-(dimethylamino)propoxy)phenethyl)-1H-pyrrole-2-
carboxamide 13f:  
1H NMR (400 MHz, DMSO-d6) δ 9.72 (br s, 1H), 8.03 (t, J = 5.2 Hz, 1H), 7.46 (d, 
J = 2.0 Hz, 1H), 7.20 (dd, J = 1.6, 8.4 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 6.82 (s, 
1H), 6.72 (s, 1H), 6.05 (m, 1H), 4.07 (t, J = 6.0 Hz, 2H), 3.40 (q, J = 6.4 Hz, 2H), 
3.23 (m, 2H), 3.10 (s, 1H), 2.82 (s, 6H), 2.76 (t, J = 6.8 Hz, 2H), 2.12 (m, 2H).  
13C NMR (100 MHz, DMSO-d6) δ 160.6, 152.7, 133.9, 132.9, 129.1, 126.3, 
121.1, 113.8, 110.9, 109.7, 108.4, 66.0, 54.3, 42.3, 40.0, 33.9, 23.8.  HRMS (Q-
TOF): m/z calc for C18H24BrN3O2
 
 [M + H]:  394.1130; found 394.1121. 
 
N-(3-bromo-4-(2-(dimethylamino)ethoxy)phenethyl)-1H-pyrrole-2-
carboxamide 13g:  
1H NMR (400 MHz, DMSO-d6) δ 10.10 (br s, 1H), 8.04 (t, J = 5.2 Hz, 1H), 7.50 
(d, J = 2.0 Hz, 1H), 7.22 (dd, J = 1.6, 8.4 Hz, 1H), 7.09 (d, J = 8.4 Hz, 1H), 6.82 
(s, 1H), 6.72 (s, 1H), 6.06 (m, 1H), 4.38 (t, J = 4.8 Hz, 2H), 3.55 (m, 2H), 3.41 (q, 
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J = 6.0 Hz, 2H), 3.21 (s, 1H), 2.92 (s, 6H), 2.77 (t, J = 6.0 Hz, 2H). 13C NMR (100 
MHz, DMSO-d6) δ 160.6, 152.2, 134.5, 133.1, 129.2, 126.3, 121.1, 113.8, 110.7, 
109.7, 108.5, 63.9, 55.5, 43.3, 39.9, 33.9.  HRMS (Q-TOF): m/z calc for C-
17H22BrN3O2
 
 [M + H]:  380.0974; found 380.0989. 
 
N-(3-bromo-4-(2-(pyrrolidin-1-yl)ethoxy)phenethyl)-1H-pyrrole-2-
carboxamide 13h:  
1H NMR (400 MHz, DMSO-d6) δ 10.10 (br s, 1H), 8.03 (t, J = 4.4 Hz, 1H), 7.50 
(d, J = 2.0 Hz, 1H), 7.22 (dd, J = 1.6, 8.4 Hz, 1H), 7.09 (d, J = 8.4 Hz, 1H), 6.82 
(s, 1H), 6.72 (s, 1H), 6.06 (m, 1H), 4.34 (t, J = 4.4 Hz, 2H), 3.64 (m, 4H), 3.41 (q, 
J = 6.0 Hz, 2H), 3.19 (m, 2H), 2.77 (t, J = 7.2 Hz, 2H), 2.04 (m, 2H), 1.86 (m, 2H). 
13C NMR (100 MHz, DMSO-d6) δ 160.6, 152.3, 134.5, 133.1, 129.2, 126.3, 
121.1, 113.8, 110.7, 109.7, 108.5, 64.8, 54.4, 52.8, 39.9, 33.9, 22.5.  HRMS (Q-
TOF): m/z calc for C19H24BrN3O2
 
 [M + H]:  406.1130; found 406.1123. 
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N-(3-bromo-4-(2-morpholinoethoxy)phenethyl)-1H-pyrrole-2-carboxamide 
13i: 
1H-nmr (400 MHz, DMSO-d6) δ 10.60 (br s, 1H), 8.04 (t, J = 5.6 Hz, 1H), 7.50 (d, 
J = 2.0 Hz, 1H), 7.32 (dd, J = 1.6, 8.8 Hz, 1H), 7.09 (d, J = 8.4 Hz, 1H), 6.82 (s, 
1H), 6.72 (s, 1H), 6.06 (m, 1H), 4.41 (t, J = 4.4 Hz, 2H), 3.99 (m, 2H), 3.74 (m, 
2H), 3.61 (t, J = 4.0 Hz, 2H), 3.58 (m, 2H), 3.41 (q, J = 6.0 Hz, 2H), 3.34 (m, 2H), 
2.77 (t, J = 6.0 Hz, 2H). 13C-nmr (100 MHz, DMSO-d6) δ 160.6, 152.2, 134.6, 
133.1, 129.2, 126.3, 121.2, 113.9, 110.7, 109.8, 108.5, 63.9, 63.4, 55.0, 52.2, 
39.9, 33.9.  HRMS (Q-TOF): m/z calc for C19H24BrN3O3 [M + H+
 
]:  422.1079; 
found 422.1086. 
 
N-(3-bromo-4-((1-methylpiperidin-3-yl)methoxy)phenethyl)-1H-pyrrole-2-
carboxamide 13j: 
1H NMR (400 MHz, DMSO-d6) δ 9.90 (br s, 1H), 8.04 (t, J = 5.2 Hz, 1H), 7.46 (d, 
J = 2.0 Hz, 1H), 7.18 (dd, J = 1.6, 8.4 Hz, 1H), 7.02 (d, J = 8.4 Hz, 1H), 6.82 (s, 
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1H), 6.73 (s, 1H), 6.06 (m, 1H), 3.97 (m, 1H), 3.89 (m, 1H), 3.55 (m, 1H), 3.40 
(m, 3H), 2.81 (m, 4H), 2.75 (t, J = 6.8 Hz, 2H), 2.37 (m, 1H), 1.88 (m, 2H), 1.74 
(m, 2H), 1.37 (m, 1H). 13C NMR (100 MHz, DMSO-d6) δ 160.6, 152.7, 134.0, 
132.9, 129.1, 126.3, 121.1, 113.9, 110.9, 109.8, 108.5, 70.3, 55.7, 53.6, 43.1, 
40.0, 34.2, 34.0, 23.9, 22.1.  HRMS (Q-TOF): m/z calc for C20H26BrN3O2
 
 [M + 
H]:  420.1287; found 420.1303. 
 
N-(3-bromo-4-(3-(dimethylamino)propoxy)phenethyl)-1-methyl-1H-pyrrole-2-
carboxamide 13k:  
1H NMR (400 MHz, DMSO- d6) δ 9.56 (br s, 1H), 8.00 (t, J = 5.6 Hz, 1H), 7.46 (d, 
J = 2.0 Hz, 1H), 7.20 (dd, J = 2.0, 8.4 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 6.86 (s, 
1H), 6.69 (m, 1H), 5.98 (t, J = 2.4 Hz, 1H), 4.08 (t, J = 6.0 Hz, 2H), 3.80 (s, 3H), 
3.35 (q, J = 6.4 Hz, 2H), 3.22 (m, 2H), 3.82 (s, 6H), 2.74 (t, J = 7.2 Hz, 2H), 2.12 
(m, 2H). 13C NMR (100 MHz, DMSO-d6) δ 161.3, 152.7, 134.0, 132.9, 129.1, 
127.5, 125.6, 113.8, 111.9, 110.8, 106.5, 66.0, 54.4, 42.4, 36.0, 33.9, 23.8.  
HRMS (Q-TOF): m/z calc for C19H26BrN3O2
 
 [M + H]:  408.1287; found 408.1292. 
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N-(3-bromo-4-(2-(dimethylamino)ethoxy)phenethyl)-1-methyl-1H-pyrrole-2-
carboxamide 13l: 
1H NMR (400 MHz, DMSO- d6) δ 10.17 (br s, 1H), 8.03 (t, J = 5.6 Hz, 1H), 7.49 
(d, J = 2.9 Hz, 1H), 7.23, (dd, J = 2.0, 8.4 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 6.86 
(s, 1H), 6.70 (m, 1H), 5.99 (t, J = 2.8 Hz, 1H), 4.38 (t, J = 5.2 Hz, 2H), 3.80 (s, 
3H), 3.56 (m, 2H), 3.37 (q, J = 6.8 Hz, 2H), 2.93 (s, 6H), 2.76 (t, J = 7.2 Hz, 2H). 
13C NMR (100 MHz, DMSO-d6) δ 161.3, 152.2, 134.6, 133.1, 129.2, 127.5, 
125.7, 113.9, 112.0, 110.7, 106.5, 64.0, 55.5, 43.3, 40.0, 36.0, 33.9.  HRMS (Q-
TOF): m/z calc for C18H24BrN3O2
 
 [M + H]:  394.1130; found 394.1133. 
 
N-(3-bromo-4-(2-(pyrrolidin-1-yl)ethoxy)phenethyl)-1-methyl-1H-pyrrole-2-
carboxamide 13m: 
1H NMR (400 MHz, DMSO- d6) δ 10.27 (br s, 1H), 8.03 (t, J = 5.6 Hz, 1H), 7.49 
(d, J = 2.0 Hz, 1H), 7.22 (dd, J = 2.0, 8.4 Hz, 1H), 7.09 (d, J = 8.4 Hz, 1H), 6.86 
(s, 1H), 6.70 (m, 1H), 5.99 (t, J = 2.8 Hz, 1H), 4.35 (t, J = 4.8 Hz, 2H), 3.80 (s, 
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3H), 3.65 (m, 4H), 3.37 (q, J = 6.8 Hz, 2H), 3.20 (m, 2H), 2.76 (t, J = 6.8 Hz, 2H), 
2.04 (m, 2H), 1.89 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ 161.3, 152.3, 
134.5, 133.1, 129.2, 127.5, 125.7, 113.8, 112.0, 110.6, 106.5, 64.8, 54.4, 52.8, 
40.0, 36.0, 33.9, 22.5.  HRMS (Q-TOF): m/z calc for C20H26BrN3O2
 
 [M + H]: 
420.1287; found 420.1272. 
 
N-(3-bromo-4-(2-morpholinoethoxy)phenethyl)-1-methyl-1H-pyrrole-2-
carboxamide 13n: 
1H-NMR (400 MHz, DMSO- d6) δ 10.72 (br s, 1H), 8.04 (t, J = 5.6 Hz, 1H), 7.49 
(d, J = 2.0 Hz, 1H), 7.23 (dd, J = 2.0, 8.4 Hz, 1H), 7.09 (d, J = 8.4 Hz, 1H), 6.86 
(s, 1H), 6.71 (m, 1H), 5.98 (t, J = 2.8 Hz, 1H), 4.42 (t, J = 4.8 Hz, 2H), 3.98 (m, 
2H), 3.80 (s, 3H), 3.76 (m, 2H), 3.62 (t, J = 4.4 Hz, 2H), 3.57 (m, 2H), 3.67 (q, J = 
6.8 Hz, 2H), 2.76 (t, J = 7.2 Hz, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 161.3, 
152.2, 134.6, 133.1, 129.2, 127.5, 125.7, 113.9, 112.0, 110.7, 106.5, 63.9, 63.4, 
55.0, 52.2, 40.0, 36.0, 33.9.  HRMS (Q-TOF): m/z calc for C20H26BrN3O3 [M + 
H+
 
]:  436.1236; found 436.1237. 
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N-(3-bromo-4-((1-methylpiperidin-3-yl)methoxy)phenethyl)-1-methyl-1H-
pyrrole-2-carboxamide 13o:  
1H NMR (400 MHz, DMSO- d6) δ 9.89 (br s, 1H), 8.02 (t, J = 5.2 Hz, 1H), 7.45 (d, 
J = 2.0 Hz, 1H), 7.19 (dd, J = 2.0, 8.4 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 6.86 (s, 
1H), 6.70 (m, 1H), 5.99 (t, J = 2.8 Hz, 1H), 4.00 (m, 1H), 3.89 (m, 1H), 3.80 (s, 
3H), 3.52 (m, 1H), 3.44 (m, 1H), 3.35 (q, J = 6.8 Hz, 2H), 2.82 (m, 4H), 2.74 (t, J 
= 7.2 Hz, 2H), 2.27 (m, 1H), 1.89 (m, 2H), 1.68 (m, 2H), 1.29 (m, 1H). 13C NMR 
(100 MHz, DMSO-d6) δ 161.3, 152.7, 134.1, 132.9, 129.1, 127.5, 125.7, 113.9, 
112.0, 110.9, 106.5, 70.3, 55.7, 53.6, 43.1, 40.0, 36.0, 34.2, 33.9, 23.9, 22.1.  
HRMS (Q-TOF): m/z calc for C21H28BrN3O2
 
 [M + H]:  434.1443; found 434.1458. 
 
4-bromo-N-(3-bromo-4-(3-(dimethylamino)propoxy)phenethyl)thiophene-2-
carboxamide 13p: 
1H NMR (400 MHz, DMSO-d6) δ 9.50 (br s, 1H), 8.65 (t, J = 5.6 Hz, 1H), 7.89 (d, 
J = 1.2 Hz, 1H), 7.75 (d, J = 1.2 Hz, 1H), 7.47 (d, J = 2.0 Hz, 1H), 7.20 (dd, J = 
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1.6, 8.4 Hz, 1H), 7.04 (d, J = 8.4 Hz, 1H), 4.09 (t, J = 6.0 Hz, 2H), 3.43 (q, J = 6.0 
Hz, 2H), 3.23 (m, 2H), 3.10 (s, 1H), 2.82 (s, 6H), 2.77 (t, J = 7.2 Hz, 2H), 2.12 (m, 
2H). 13C NMR (100 MHz, DMSO-d6) δ 159.8, 152.8, 141.1, 133.6, 132.9, 129.7, 
129.1, 128.5, 113.8, 110.9, 108.6, 66.0, 54.4, 42.4, 40.6, 33.5, 23.8.  HRMS (Q-
TOF): m/z calc for C18H22Br2N2O2
 
S [M + H]:  488.9847; found 488.9845. 
 
4-bromo-N-(3-bromo-4-(2-(dimethylamino)ethoxy)phenethyl)thiophene-2-
carboxamide 13q: 
1H NMR (400 MHz, DMSO-d6) δ 9.85 (br s, 1H), 8.66 (t, J = 5.2 Hz, 1H), 7.89 (d, 
J = 0.8 Hz, 1H), 7.76 (d, J = 0.8 Hz, 1H), 7.50 (d, J = 1.6 Hz, 1H), 7.23 (dd, J = 
1.6, 8.4 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 4.37 (t, J = 4.8 Hz, 2H), 3.50 (m, 4H), 
3.21 (s, 1H), 2.92 (s, 6H), 2.78 (t, J = 7.2 Hz, 2H). 13C NMR (100 MHz, DMSO-
d6) δ 159.8, 152.3, 141.1, 134.2, 133.1, 129.7, 129.2, 128.5, 113.9, 110.7, 108.6, 
63.9, 55.5, 43.4, 40.6, 33.5.  HRMS (Q-TOF): m/z calc for C17H20Br2N2O2
 
S [M + 
H]:  474.9690; found 474.9705. 
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4-bromo-N-(3-bromo-4-(2-(pyrrolidin-1-yl)ethoxy)phenethyl)thiophene-2-
carboxamide 13r: 
1H NMR (400 MHz, DMSO-d6) δ 10.08 (br s, 1H), 8.66 (t, J = 5.6 Hz, 1H), 7.89 
(d, J = 1.6 Hz, 1H), 7.76 (d, J = 1.6 Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.23 (dd, J 
= 2.0, 8.4 Hz, 1H), 7.10 (d, J = 8.4 Hz, 1H), 4.35 (t, J = 4.8 Hz, 2H), 3.63 (m, 4H), 
3.43 (q, J = 6.8 Hz, 2H), 3.19 (m, 2H), 2.78 (t, J = 7.2 Hz, 2H), 2.04 (m, 2H), 1.87 
(m, 2H). 13C NMR (100 MHz, DMSO-d6) δ 159.7, 152.3, 134.1, 133.2, 129.7, 
129.2, 128.5, 113.8, 64.7, 54.4, 52.8, 40.6, 35.7, 33.8, 22.5.  HRMS (Q-TOF): 
m/z calc for C19H22Br2N2O2
 
S [M + H]:  500.9847; found 500.9847. 
 
4-bromo-N-(3-bromo-4-(2-morpholinoethoxy)phenethyl)thiophene-2-
carboxamide 13s: 
1H-NMR (400 MHz, DMSO-d6) δ 10.32 (br s, 1H), 8.67 (t, J = 5.6 Hz, 1H), 7.89 
(d, J = 1.2 Hz, 1H), 7.76 (d, J = 1.2 Hz, 1H), 7.50 (d, J = 2.0 Hz, 1H), 7.23 (dd, J 
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= 1.6, 8.4 Hz, 1H), 7.10 (d, J = 8.4 Hz, 1H), 4.40 (t, J = 2.8 Hz, 2H), 3.98 (m, 2H), 
3.80 (m, 2H), 3.60 (m, 2H), 3.43 (q, J = 6.8 Hz, 2H), 3.34 (m, 2H), 2.78 (t, J = 6.8 
Hz, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 159.8, 152.3, 141.1, 134.2, 133.1, 
129.7, 129.2, 128.5, 113.9, 110.7, 108.6, 63.9, 63.4, 55.0, 52.2, 40.6, 33.5.  
HRMS (Q-TOF): m/z calc for C19H22Br2N2O3S [M + H+
 
]:  516.9796; found 
516.9796. 
 
4-bromo-N-(3-bromo-4-((1-methylpiperidin-3-yl)methoxy)phenethyl) 
thiophene-2-carboxamide 13t:  
1H NMR (400 MHz, DMSO-d6) δ 9.62 (br s, 1H), 8.65 (t, J = 5.6 Hz, 1H), 7.89 (d, 
J = 1.2 Hz, 1H), 7.57 (d, J = 1.2 Hz, 1H), 7.47 (d, J = 1.6 Hz, 1H), 7.19 (dd, J = 
1.6, 8.4 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 4.00 (m, 1H), 3.89 (m, 1H), 3.51 (m, 
1H), 3.43 (m, 3H), 2.81 (m, 6H), 2.25 (m, 1H), 1.89 (m, 2H), 1.70 (m, 2H), 1.29 
(m, 1H). 13C NMR (100 MHz, DMSO-d6) δ 159.8, 152.7, 141.1, 133.6, 133.0, 
129.7, 129.2, 128.5, 113.9, 110.9, 108.6, 70.3, 55.7, 53.7, 43.1, 40.6, 34.3, 33.5, 
23.9, 22.1.  HRMS (Q-TOF): m/z calc for C20H24Br2N2O2
 
S [M + H]:  515.0003; 
found 515.0017. 
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5-bromo-N-(3-bromo-4-(3-(dimethylamino)propoxy)phenethyl)furan-2-
carboxamide 13u:  
1H NMR (400 MHz, DMSO-d6) δ 9.52 (br s, 1H), 8.48 (t, J = 5.6 Hz, 1H), 7.45 (d, 
J = 2.0 Hz, 1H), 7.19 (dd, J = 2.0, 8.4 Hz, 1H), 7.10 (d, J = 3.6 Hz, 1H), 7.03 (d, J 
= 8.4 Hz, 1H), 6.74 (d, J = 3.6 Hz, 1H), 4.09 (t, J = 6.0 Hz, 2H), 3.39 (q, J = 6.8 
Hz, 2H), 3.23 (m, 2H), 2.83 (s, 6H), 2.76 (t, J = 7.2 Hz, 2H), 2.10 (m, 2H). 13C 
NMR (100 MHz, DMSO-d6) δ 156.6, 152.8, 149.7, 133.6, 132.9, 129.1, 124.2, 
115.6, 113.9, 110.9, 66.0, 54.4, 42.4, 33.5, 23.8.  HRMS (Q-TOF): m/z calc for C-
18H22Br2N2O3
 
 [M + H]:  473.0075; found 473.0067. 
 
5-bromo-N-(3-bromo-4-(2-(dimethylamino)ethoxy)phenethyl)furan-2-
carboxamide 13v:  
1H NMR (400 MHz, DMSO-d6) δ 10.08 (br s, 1H), 8.50 (t, J = 5.6 Hz, 2H), 7.48 
(d, J = 1.6 Hz, 1H), 7.21 (dd, J = 1.6, 8.4 Hz, 1H), 7.10 (m, 2H), 6.73 (d, J = 3.6 
Hz, 1H), 4.38 (t, J = 4.8 Hz, 2H), 3.55 (m, 2H), 3.40 (q, J = 6.8 Hz, 2H), 2.77 (t, J 
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= 6.8 Hz, 2H). 13C NMR (100 MHz, DMSO-d6) δ 156.6, 152.3, 149.7, 134.2, 
133.1, 129.2, 124.2, 115.6, 113.9, 113.8, 110.7, 63.9, 55.5, 43.3, 40.0, 33.6.  
HRMS (Q-TOF): m/z calc for C17H20Br2N2O3
 
 [M + H]:  458.9919; found 
458.9916. 
 
5-bromo-N-(3-bromo-4-(2-(pyrrolidin-1-yl)ethoxy)phenethyl)furan-2-
carboxamide 13w:  
1H NMR (400 MHz, DMSO-d6) δ 10.2, 8.50 (t, J = 5.6 Hz, 1H), 7.48 (d, J = 1.2 
Hz, 1H), 7.21 (dd, J = 1.6, 8.4 Hz, 1H), 7.10 (m, 2H), 6.73 (d, J = 3.6 Hz, 1H), 
4.35 (t, J = 4.8 Hz, 2H), 3.64 (m, 4H), 3.40 (q, J = 6.8 Hz, 2H), 3.24 (m, 2H), 2.77 
(t, J = 7.2 Hz, 2H), 2.04 (m, 2H), 1.89 (m, 2H). 13C NMR(100 MHz, DMSO-d6) δ 
156.6, 152.3, 149.7, 134.1, 133.1, 129.2, 124.2, 115.6, 113.9, 113.8, 110.6, 64.7, 
54.4, 52.8, 39.9, 33.6, 22.5.  HRMS (Q-TOF): m/z calc for C19H22Br2N2O3
 
 [M + 
H]:  485.0075; found 485.0087. 
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5-bromo-N-(3-bromo-4-(2-morpholinoethoxy)phenethyl)furan-2-
carboxamide 13x: 
1H NMR (400 MHz, DMSO-d6) δ 10.55 (br s, 1H), 8.50 (t, J = 5.6 Hz, 1H), 7.48 
(d, J = 1.6 Hz, 1H), 7.21 (dd, J = 1.6, 8.4 Hz, 1H), 7.10 (m, 2H), 6.73 (d, J = 3.6 
Hz, 1H), 4.41 (t, J = 4.8 Hz, 2H), 3.98 (m, 2H), 3.74 (m, 2H), 3.61 (m, 2H), 3.58 
(m, 2H), 3.40 (q, J = 6.8 Hz, 2H), 3.34 (m, 2H), 2.77 (t, J = 6.8 Hz, 2H). 13C NMR 
(100 MHz, DMSO-d6) δ 156.6, 152.3, 149.7, 134.2, 133.1, 129.2, 124.2, 115.6, 
113.9, 110.7, 63.9, 63.3, 55.0, 52.2, 39.9, 33.6.  HRMS (Q-TOF): m/z calc for C-
19H22Br2N2O4 [M + H+
 
]:  501.0025; found 501.0031. 
 
5-bromo-N-(3-bromo-4-((1-methylpiperidin-3-yl)methoxy)phenethyl)furan-2-
carboxamide 13y:  
1H NMR (400 MHz, DMSO-d6) δ 9.58 (br s, 1H), 8.48 (t, J = 5.6 Hz, 1H), 7.45 (d, 
J = 2.0 Hz, 1H), 7.17 (dd, J = 1.6, 8.4 Hz, 1H), 7.09 (d, J = 3.6 Hz, 1H), 7.03 (d, J 
= 8.4 Hz, 1H), 6.73 (d, J = 3.6 Hz, 1H), 3.99 (m, 1H), 3.89 (m, 1H), 3.52 (m, 1H), 
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3.41 (m, 3H), 2.81 (m, 6H), 2.49 (m, 1H), 1.89 (m, 2H), 1.70 (m, 2H), 1.29 (m, 
1H). 13C NMR (100 MHz, DMSO-d6) δ 156.6, 152.7, 149.7, 133.7, 132.9, 129.1, 
124.2, 115.6, 113.9, 113.8, 110.9, 70.3, 55.7, 53.6, 43.2, 34.3, 33.6, 23.9, 22.1.  
HRMS (Q-TOF): m/z calc for C20H24Br2N2O3
 
 [M + H]:  499.0232; found 
499.0251. 
General Synthetic Scheme 2. 
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Phthalimide Formation Step:   
A 20 mL microwave vial containing I-1 (1 equivalent), and phthalic anhydride (1 
equivalent), was capped and heated to 160 oC for 20 min.  The solid was 
dissolved in hot EtOAc and left to crystallize overnight.  The crystals were filtered 
and washed with ether to obtain II-1 as a white solid (94% yield). 
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2-(3-bromo-4-methoxyphenethyl)isoindoline-1,3-dione 21: 1H NMR (400 
MHz, DMSO-d6
 
) δ 7.83 (m, 4H), 7.41 (d, J = 1.6 Hz, 1H), 7.13 (dd, J = 8.4, 
2.0Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 3.78 (m, 5H), 2.86 (t, J = 7.2 Hz, 2H).  
LCMS, single peak, 3.43 min, m/e, 360.0 (M+1) 
Deprotection Step for Phthalimide Library:   
To a stirred solution of protected material II-1 (1 equivalent) in anhydrous CH2Cl2 
under argon at -78 oC was added BBr3 (4 equivalents of 1.0 M solution in 
CH2Cl2) over 20 minutes.  The solution was stirred at -78 oC for 30 minutes and 
then allowed to warm to 25 oC for 1.5 hours.  The reaction was slowly quenched 
with saturated aqueous NaHCO3 until slightly basic by pH paper.  This solution 
was added to a separatory funnel containing water and extracted 3x with CH2Cl2.  
The combined organic layers were washed with saturated aqueous brine 
solution.  The organic layer was dried over MgSO4, and concentrated in vacuo to 
yield the deprotected product II-3 (100 % yield).  This material was used without 
further purification. 
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2-(3-bromo-4-hydroxyphenethyl)isoindoline-1,3-dione 22:  
1H NMR (400 MHz, DMSO-d6
 
) δ 10.03 (s, 1H), 7.83 )m, 4H), 7.29 (d, J = 1.6 Hz, 
1H), 6.96 (dd, J = 8.4, 2.0 Hz, 1H), 6.79 (d, J = 8.0 Hz, 1H), 3.75 (t, J = 7.2 Hz, 
2H), 2.80 (t, J = 7.2 Hz, 2H);  LCMS, single peak, 2.98 min, m/e, 346.0 (M+1). 
Alkylation step for Phthalimide Library:   
In a 200 mL round bottom flask containing II-3 (1 equivalent), alkyl halide (2 
equivalents), KI (2 equivalents), and Cs2CO3 (2 equivalents) was added 
anhydrous DMF, 30 mL which was heated to reflux overnight.  The reaction was 
added to a seperatory funnel containing water and extracted 2x with EtOAc.  The 
combined organic layers were washed with saturated aqueous brine solution. 
The organic layer was dried over MgSO4
 
, and concentrated in vacuo to yield II-4.  
This material was used immediately without further purification. 
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Deprotection step for Phthalimide Library:   
A 20 mL microwave vial containing II-4 (1 equivalent) ethanol, 10 mL, and 
hydrazine hydrate (10 equivalents), was capped and heated to 120 o
 
C for 20 min.  
The solution was immediately added to a SCX cartridge and washed 5x with 
methanol.  The cartidge was then washed 2x with 2M ammonia in methanol and 
concentrated in vacuo to yield II-5 (60% yield over 2 steps). 
 
2-(3-bromo-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)ethanamine 25:  
1H NMR (400 MHz, DMSO-d6
 
) δ 7.38 (d, J = 2.0 Hz, 1H), 7.12 (dd, J = 8.4, 1.6 
Hz, 1H), 6.99 (d, J = 8.4 Hz, 1H), 4.08 (t, J = 5.6 Hz, 2H), 2.78 (t, J = 5.6 Hz, 2H), 
2.71 (m, 4H), 2.55 (m, 6H), 1.65 (m, 4H);  LCMS, single peak, 1.60 min, m/e, 
313.1 (M+1). 
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Coupling Step For Phthalimide Library:   
To a stirred solution of acid R1COOH (1 equivalent), HOBt (2.1 equivalents), and 
amine II-5 (1 equivalent) in 9:1 CH2Cl2:DIEA at 25 o
 
C was added DIC (2 
equivalents) and the mixture was stirred overnight. The reaction was filtered, 
concentrated in vacuo and purified via mass directed HPLC to obtain pure II-6 as 
the TFA salt (50-95% yield). 
 
N-(3-bromo-4-(2-(pyrrolidin-1-yl)ethoxy)phenethyl)thiazole-5-carboxamide 
26d:  
1H NMR (400 MHz, CDCl3
 
) δ 7.84 (d, J = 3.2 Hz, 1H), 7.57 (d, J = 3.2 Hz, 1H), 
7.44 (d, J = 2.0 Hz, 1H), 7.15 (dd, J = 8.4, 2.0 Hz, 1H), 6.83 (d, J = 8.4 Hz, 1H), 
4.41 (m, 2H), 3.95 (m, 2H), 3.67 (q, J = 6.8 Hz, 2H), 3.15 (m, 2H), 2.87 (t, J = 6.8 
Hz, 2H), 2.15 (m, 6H);  LCMS, single peak, 2.27 min, m/e, 424.1 (M+1). 
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General Synthetic Scheme 3. 
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Coupling step:   
To a stirred solution of acid R1COOH (1 equivalent), HOBt (2.1 equivalents), and 
amine I-1 (1 equivalent) in 9:1 CH2Cl2:DIEA at 25oC was added DIC (2 
equivalents) and the mixture was stirred overnight.  After quenching with water, 
the reaction was added to a separatory funnel and extracted 3x with CH2Cl2.  
The organic layers were combined, and washed with saturated aqueous brine 
solution.  The organic layer was dried over MgSO4, and concentrated in vacuo.  
The crude material was then subjected to flash chromatography to give pure III-1 
as a white solid (93 % yield). 
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Deprotection Step:   
To a stirred solution of coupled material III-1 (1 equivalent) in anhydrous CH2Cl2 
under argon at -78 oC was added BBr3 (4 equivalents of 1.0 M solution in 
CH2Cl2) over 20 minutes.  The solution was stirred at -78 oC for 30 minutes and 
then allowed to warm to 25 oC for 1.5 hours.  The reaction was slowly quenched 
with saturated aqueous NaHCO3 until slightly basic by pH paper.  This solution 
was added to a separatory funnel containing water and extracted 3x with CH2Cl2.  
The combined organic layers were washed with saturated aqueous brine 
solution.  The organic layer was dried over MgSO4
 
, and concentrated in vacuo to 
yield the deprotected product III-2 (92 % yield).  This material was used without 
further purification. 
Alkylation step:  
In a 20 mL microwave vial containing III-2 (1 equivalent), alkyl halide (4 
equivalents), KI (2 equivalents), and Cs2CO3 (2 equivalents) was added 
anhydrous DMF, 10 mL.  This was heated under microwave conditions at 120 oC 
for 60 minutes.  The reaction was added to a seperatory funnel containing water 
and extracted 3x with EtOAc.  The combined organic layers were washed with 
saturated aqueous brine solution.  The organic layer was dried with MgSO4 
concentrated in vacuo.  This was filtered through a silica plug, washed 3x with 
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EtOAc, and concentrated in vacuo to yield III-3 (100 %).  This material was used 
without further purification. 
 
 
4-bromo-N-(3-bromo-4-(2,2-dimethoxyethoxy)phenethyl)thiophene-2-
carboxamide 16:  
1H NMR (400 MHz, DMSO-d6
 
) δ 8.64 (t, J = 5.2 Hz, 1H), 7.88 (s, 1H), 7.75 (s, 
1H), 7.45 (d, J = 2.0 Hz, 1H), 7.16 (dd, J = 8.4, 1.6 Hz, 1H), 7.06 (d, J = 8.4, 1H), 
4.68 (t, J = 5.2 Hz, 1H), 4.00 (d, J = 7.2 Hz, 2H), 3.42 (q, J = 6.0 Hz, 2H), 3.37 (s, 
6H), 2.76 (t, J = 6.8 Hz, 2H). 
Aldehyde generation:  
A 20 mL microwave vial containing III-3 (1 equivalent) 1,2 dichloroethane, 10 mL, 
TFA (2 equivalents), and water (2 equivalents), was capped and heated to 100 
o
 
C for 60 min.  This was concentrated in vacuo and used without any further 
purification. 
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Reductive amination:   
To a 20 mL vial containing III-4 and 9:1 DCM:MeOH, 10 mL, was added PS-
triacetoxyborohydride (5 equivalents), and amine (5 equivalents), which was 
agitated overnight.  The reaction was concentrated in vacuo and purified via 
mass directed HPLC to obtain pure III-6 as the TFA salt (15-70% yield). 
 
 
(R)-4-bromo-N-(3-bromo-4-(2-(2-methylpyrrolidin-1-yl)ethoxy)phenethyl) 
thiophene-2-carboxamide 18b:  
1H NMR (400 MHz, DMSO-d6
 
) δ 9.86 (br s, 1H), 8.70 (t, J = 5.6 Hz, 1H), 7.88 (s, 
1H), 7.77 (s, 1H), 7.50 (d, J = 2.0 Hz, 1H), 7.23 (dd, J = 8.4, 2.0 Hz, 1H), 7.07 (d, 
J = 8.4 Hz, 1H), 4.35 (m, 2H), 3.75 (m, 2H), 3.52 (m, 2H), 3.43 (q, J = 6.8 Hz, 
2H), 3.33 (m, 1H), 2.78 (t, J = 7.2 Hz, 2H), 2.21 (m, 1H), 1.94 (m, 2H), 1.60 (m, 
1H), 1.38 (d, J = 6.4 Hz, 3H);  LCMS, single peak, 2.65 min, m/e, 515.0 (M+1). 
 
 
 60 
 
H3 Radioligand Binding Assay.   
All in vitro pharmacology was performed by MDS Pharma services as a fee for 
service arrangement including the large panel ancillary pharmacology screens 
(Lead Profile screen) and the H3 assays.  The H3 radioligand assay (MDS 
catalogue #: 239810) employed human recombinant Chinese Hamster Ovary 
(CHO)-K1 cells and 3 nM [3H] R(-)-α-methylhistamine (RAMH) as the radioligand 
with 5-point concentration response curves to arrive at Ki (bindng) and/or IC50 
(inhibition) values following published assay protocols (21, 22).  Basic assay 
methods:  Vehicle (1% DMSO), Incubation time/temperature (90 minutes @ 25 
oC), Incubation buffer (50 mM TRis-HCl, pH 7.4, 5 mM MgCl2, 0.04% BSA), 
ligand ([3H] R(-)-α-methylhistamine), Kd (2.4 nM), Bmax
 
 (4.2 pmole/mg protein), 
specific binding (95%), quantitation method (radioligand binding), significance 
criteria (>50% stimulation or inhibition).     
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CHAPTER II 
 
SYNTHESIS AND DESIGN OF SELECTIVE M4
 
 MUSCARINIC MODULATORS 
 The five subtypes of the mammalian muscarinic acetylcholine receptor 
(mAChR1-5 or M1-5) are differentially expressed GPCRs important to a variety of 
physiological functions, including attention, learning and memory, pain, sleep, 
movement, gastrointestinal motility, and cardiovascular regulation, among others 
(4-7).  Based on a wide body of data, muscarinic receptors are considered 
potential therapeutic targets for numerous CNS diseases and disorders such as 
Alzheimer’s disease and Schizophrenia (10-12).  However, due to high sequence 
conservation of the orthosteric binding site across subtypes, discovery of truly 
subtype-selective compounds has proven historically challenging.  Indeed, M2 
and M3
 M
 related side effects (e.g. GI disturbance, salivation, lacrimation, and 
bradycardia) have contributed to failure in the clinical development of muscarinic 
agonists despite promising demonstrations of therapeutic efficacy (9,10). 
Furthermore, deep biological insight into the specific roles of the mAChRs in both 
basic neurobiology and CNS pathologies has been hindered by the paucity of 
selective tools. 
4 activation in particular has been hypothesized to possess therapeutic 
potential in the treatment of psychosis based on the M4 localization and M4 
knockout mouse data (24-26).  Although M4 receptors are expressed throughout 
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the CNS, highest expression is found in the hippocampus, midbrain, and striatal 
regions where it is believed to play important roles in both cognitive functions and 
in regulation of dopamine (DA) signaling.  The positive symptoms of 
Schizophrenia are primarily linked to hyperactivity of the mesolimbic DA pathway, 
Figure 1, which is comprised of DA neurons originating in the mid-brain ventral 
tegmental area (VTA), which project to the nucleus accumbens (NAcc) (27-29). 
 
 
Figure 1.  Simplified diagram of mesolimbic dopamine signaling pathway. 
 
 Within this pathway, M4 is believed to exert regulatory control over Ach 
release from hindbrain cholinergic neurons that innervate the VTA.  Thus 
activation of M4
 Additional support for M
 autoreceptors in this brain region may result in decreased DA 
signaling in the forebrain. 
4 as a therapeutic target for Schizophrenia comes 
from findings with the M1/M4 agonist Xanomeline 1, Figure 2, which showed 
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robust clinical efficacy in reduction of positive, negative, and cognition symptoms 
(29-31).  However, due to lack of true selectivity, M2/M3 mediated side effects 
precluded successful development of Xanomeline.  It has remained a 
longstanding question in the field as to what contribution M1 and M4 made to the 
efficacy of Xanomeline 1.  Therefore, attainment of a truly M4
The additional DMPK related challenges inherent to CNS drug discovery 
have also hampered progress in this area.  Despite these hurdles, a number of 
novel subtype-selective and centrally penetrant muscarinic compounds, including 
agonists, antagonists, and potentiators, have recently emerged from functional 
cell-based screening approaches (13-17).  The discovery and development of 
these first selective muscarinic modulators around the structure VU0010010 2, 
and the rational for the design of these compounds was a major undertaking 
during the early stages of this program.  Initial optimization focused on improving 
the physiochemical properties of lead compound VU0010010 2, which 
possessed an EC
 selective small 
molecule would provide deeper insight. 
50 value of 400 nM and elicited a 47-fold leftward shift of an 
ACh concentration-response curve (CRC) by Ca2+ mobilization assay in rat 
M4/Gqi5
 For the chemical optimization of VU0010010 2, Figure 2, we undertook a 
diversity-oriented synthesis approach to explode structure-activity relationships 
(SAR) with a variety of hypothesis-driven structural changes to the lead 
compound. 
- expressing cells, but suffered from solubility issues and lack of brain 
penetration. 
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Figure 2.  Structure of Xanomeline, 1, and VU0010010, 2. 
 
The rationale for this approach for the optimization of VU0010010, 2 is 
that SAR for allosteric ligands is often “flat” or “shallow”, with subtle structural 
modifications leading to a complete loss of activity, and often only one portion of 
an allosteric ligand is amenable to change.  Therefore, a multidimensional 
diversity-oriented synthesis library approach provides the best opportunity to 
quickly identify productive SAR as opposed to a lead optimization strategy based 
on classical, single compound synthesis (1-2).  One explanation for the lack of 
central activity observed with VU0010010, 2, could be the result of the poor 
physiochemical properties alone or in combination with P-glycoprotein (P-gp) 
efflux.  P-gp is an efflux transporter with broad substrate specificity present on 
the luminal membrane of epithelial cells comprising the blood-brain barrier, which 
is known to impair the brain penetrability of a number of drugs.  The β-
aminoamide motif 3 present in VU0010010 represents a potential P-gp liability, 
which could be removed by cyclization to analogs such as 4, Figure 3, and the 
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dimethyl functionality can be a potential CYP450
 
 site of metabolism, leading to 
increased clearance. 
 
Figure 3.  Rational for Library Design arounde VU0010010. 
 
Alternatively, P-gp susceptibility could also be diminished by electronically 
attenuating the basicity of the amine moieties by the incorporation of distal 
fluorine atoms.  Utilizing solution phase parallel synthesis, Figure 4, we 
synthesized small 12 to 24-member focused libraries around each of the 9 
scaffolds, 4 and 7 through 15, Figure 4, which were then purified by mass-
directed preparative HPLC to analytical purity (>98%).   
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Figure 4.  Synthesis and chemical optimization of lead compound VU0010010, 
1. 
 
This collection of VU0010010 analogs incorporated CF3 moieties, 
scaffolds 9 and 10, to electronically attenuate potential P-gp susceptibility, 
deletion of the amino moiety, scaffold 14, or replacement of the β-amino moiety 
with an isosteric methyl group, scaffold 13.  Other scaffolds explored the deletion 
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of substituents on the pyridine nucleus, scaffold 11, incorporation of an additional 
nitrogen atom to afford a pyrimidine nucleus, scaffold 12, or removal of the 
pyridine nitrogen atom in VU0010010, scaffold 15.  Finally, scaffold 7 focused on 
maintaining the core structure of VU0010010 but explored alternative amides 
selected to improve physiochemical properties and lower the log P value. 
As observed with positive allosteric modulators of class C GPCRs, SAR 
around VU0010010 was relatively flat, possibly due to a shallow binding pocket 
(1-2).  An EC20 triage screen, employing a functional fluorescence-based Ca2+ 
assay in CHO cells stably coexpressing the rat M4 mAChR and the chimeric G 
protein, Gqi5, quickly eliminated all VU0010010 analogs with the exception of 
those in library 7, built around the original lead thienopyridine scaffold.  Within 
library 7, all aliphatic and nonbenzyl amides were inactive, and only benzyl and 
heteroaryl methyl congeners of VU0010010, compounds 7a through 7p, retained 
M4 PAM activity, Table 1.  Analogs were synthesized utilizing resin bound 
peptide coupling techniques, and purified via mass directed HPLC.  To identify 
compounds that potentiated agonist activation of M4, the response to an EC20 
concentration of ACh was determined in the absence and presence of test 
compound.  The potency of each compound was determined by preincubating 
cells with vehicle or increasing concentrations of test compound followed by the 
addition of an EC20 concentration of ACh to yield concentration response curves 
(CRCs).  Subtle substitution changes on the arene ring lost activity 5 to 10-fold in 
terms of M4 EC50 and/or -fold shift of the ACh CRC, Table 1.  Compound 7d, in 
which the 4-Cl moiety of VU0010010 is moved to the 3-position, results in a loss 
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in potency of over 9-fold (EC50 = 3.7 µM).  The unsubstituted phenyl congener 7a 
retains M4 PAM activity (EC50 = 630 nM), but the -fold shift diminishes to 8.6-fold 
versus the 47-fold shift observed for VU0010010 (3).  In general, functionalized 
benzyl amides, as well as pyridyl methyl congeners, compounds 7f and 7g, were 
well tolerated, providing selective M4 PAMs with EC50
 
 values ranging from 380 
nM to 3.7 µM and with -fold shifts of the ACh dose-response curve from 8.6 to 
70-fold. 
 
Table 1.  Structures, activities, and ACh CRC -fold shifts of M4 PAM analogs 7. 
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Although, these compounds increase the potency of ACh at M4, they lack 
intrinsic agonist activity on their own.  Initial optimization focused on improving 
the physio-chemical properties of lead compound VU0010010 1, which 
possesses a 400 nM EC50 and caused a 47-fold leftward shift of an ACh 
concentration response curve (CRC) by Ca2+ mobilization in rat M4/Gqi5
 
-
expressing cells, but suffered from solubility issues and lack of brain penetration.  
Analogs, VU0152099 7o and VU0152100 7p, which had similar potency and 
comparable efficacy to the parent compound VU0010010 1 but were centrally 
penetrant and displayed in vivo activity in a rodent behavioral model predictive of 
antipsychotic efficacy.  These compounds were also devoid of ancillary 
pharmacological activity across a large number of off-target GPCRs, ion 
channels, and enzymes.  Despite the utility of 7o and 7p for in vitro and in vivo 
pharmacological studies, we sought to further explore the SAR of this series with 
a more exhaustive optimization campaign by employing an iterative analog 
library approach.  The rationale for this effort stemmed in part from the rodent 
DMPK profiles of these ‘first generation’ analogs 7o and 7p, Figure 5, which 
were adequate but not ideal. 
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Figure 5.  First-Generation Library Leads from Optimization of VU0010010. 
 
 Having tentatively designated the p-methoxybenzamide of 7p as favored 
based on its in vitro activity at M4
 
, we first held this side chain constant during 
derivatization of the pyridine core at the 6-position.  This was also chosen in part 
to address metabolic hydroxylation liability at the 5-position.  Synthesis of initial 
20-member alkylamine library, as shown in Scheme 1, began with condensation 
between 3-aminocrotonitrile 16 and 2-cyanothioacetamide 17 to furnish the 
aminopyridyl core 18 (19).  This was cyclized with α-chloro-p-methoxybenzamide 
19 to give the diaminothienopyridine scaffold with the p-methoxybenzamide 20.  
To produce the 20-member amine library, 20 was reacted with various alkyl 
chlorides to generate 21a-p.  The ether library was synthesized in a similar 
fashion Scheme 2.  Ethylacetoacetate 22 was reacted with 2-
cyanothioacetamide 17 to provide the core pyridone 23, (19) which was then 
cyclized with 19 and finally alkylated to obtain analogs 25a-s. 
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Scheme 1.  Synthesis of amine analog libraries 21a-p. 
 
 These ‘second generation’ libraries were first screened in a single-point 
Ca2+ mobilization assay using a fixed 10 µM compound concentration added to 
rM4/Gqi5-cells prior to addition of a submaximal concentration (~EC20) of ACh.  
This allowed efficient triage of analogs for further characterization.  In general, 
alkylamine library 21a-p showed weak efficacy with elevation of the ACh 
response ranging from none (inactive) to modest (<50% ACh max).  However, 
ether library 25a-s contained a number of robust potentiators (>60% to 90% ACh 
Max).  EC50
 
 values for compounds selected from both libraries based on their 
potentiation efficacy and structural characteristics were then obtained from full 
CRC assays, Table 2. 
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Scheme 2.  Synthesis of ether analog libraries 25a-s. 
 
 More than half of these compounds possessed EC50 values over 10 µM 
with potentiation effects emerging only at the 10 µM and 30 µM concentrations.  
Among alkylamines 21a-s, only the ethyl morpholine congener 21c had an EC50 
just below 10 µM, reflecting relatively weak activity of this library.  In contrast, 
compounds chosen from the ether library 25a-s possessed better potencies.  
Particularly, the picolyl analogs 25k, 25l, and 25m each exhibited an EC50 of 
approximately 2 µM.  A full concentration response curve for 25k in the presence 
of fixed ACh EC20 is presented in Figure 6.  25k elicited a robust potentiation of 
M4 activation, elevating the submaximal ACh response to over 130% of the 
maximum response induced by a high concentration of ACh alone.  Looking 
ahead to in vivo vehicle formulations, the structure of 25k was particularly 
advantageous, as the presence of a basic amine would allow for an HCl salt to 
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confer greater aqueous vehicle solubility.  Based on these potency data, the six 
compounds having EC50 values below 10 µM were examined for their ability to 
leftshift a full ACh CRC when applied at a fixed 30 µM concentration in a similar 
functional Ca2+ assay with rM4/Gqi5
 As shown in Table 2, neither morpholino compound 21c nor ethyl 
compound 21p caused a leftward shift in the ACh CRC thus demonstrating the 
compromised activity found with alkylamine modification at the 6-position of the 
scaffold.  The same lack of effect was seen with the tertiary amine analog 25a 
from the ether library.  However, the ether linked morpholino 25c and pyrrolidine 
25d analogs demonstrated strong respective 37x and 25x foldshift effects.  
Interestingly, movement of the nitrogen from the 2-position or 3-position of the 
picolyl ethers 25m and 25l to the 4-position of 25k, Table 2, progressively 
increased the foldshift from 5x to 9x and ultimately 50x, respectively.  
-cells (i.e. foldshift assay).  In the case of 
other allosteric potentiators of GPCRs, compound potency often fails to correlate 
tightly with foldshift.  For example, a compound with high potency but low efficacy 
can exhibit next to no foldshift, and conversely a compound with low potency but 
high efficacy can exhibit a substantial foldshift.  Hence, evaluation of foldshift for 
novel potentiators having upper single-digit micromolar potencies can sometimes 
uncover SAR that would have otherwise been missed. 
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Table 2.  Structures, activities, and ACh CRC -fold shifts of M4
 
 PAM analog 
libraries 21 and 25. 
 Taken together, these data suggested ether-linked modifications to the 6-
position of the scaffold were more tolerated than alkylamine-linked changes. 
However, despite retention of robust potentiation properties in terms of foldshift 
for 25c, 25d, and especially 25k, the potency of these analogs was moderately 
diminished relative to parent compound VU0152100, 7p.  Furthermore, the SAR 
for these two libraries underlines the aforementioned importance of considering 
 79 
both foldshift and potency when evaluating allosteric potentiators.  Although each 
of the three picolyl ether analogs had ~2 µM EC50
 For the next library iteration, we postulated that with the picolyl or ethyl 
morpholine ether moieties on the left-hand side of the molecule, the p-
methoxybenzyl on the right-hand side might no longer be the favored amide side 
chain.  We considered that a different side chain could allow retention of strong 
potentiator activity and at the same time return the sub-micromolar potency of the 
parent structure.  To this end, we opted to re-scan with approximately 18 side 
chain groups while holding constant each of the three picolyl ether modifications, 
the morpholino ether, and the dimethylpropylamine ether.  The morpholino and 4-
picolyl were clear choices based on their degree of foldshift, but the 2-picolyl and 
3-picolyl were also included to be comprehensive.  Likewise, the 
dimethylpropylamine ether was used to provide for the possibility that a different 
amide side chain may rescue the activity of 25a (i.e. a matrix-like approach to 
broaden SAR). 
 values, their potentiation 
effects on the ACh CRC revealed dramatic differences in efficacy. 
 
 80 
 
Figure 6.  Potentiation effects of 25k at rM4 by functional Ca2+ mobilization 
assay.  (A, left) Concentration response curve for 25k in the presence of a fixed 
submaximal concentration of ACh (~EC20
 
). (B, right) Full concentration response 
curve for ACh in the presence and absence of a fixed 30 µM concentration of 
25k.  All data represent the mean values of at least three experiments with 
similar results. 
 These third generation libraries began with the cyclization between 
pyridone 23 and ethyl chloroacetate 26 to produce thienopyridone ethyl ester 27.  
To obtain the five alkyl ethers 28a-e, 27 was reacted with the five selected side 
chains from our previously mentioned second generation library.  These five 
scaffolds were saponified and immediately coupled with 18 amines to produce 
five alkyl ether libraries with different amide side chains 29a-p, 30a-r, 31a-o, 32a-
p, 33a-o, Scheme 3. 
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Scheme 3.  Synthesis of analog libraries 29-33, utilizing the 5 best alkyl ether 
functional groups. 
 
 As before, these libraries were screened first in a single-point 10 µM 
potentiation assay that tested their ability to enhance the response of a 
submaximal (~EC20) concentration of ACh in rM4/Gqi5
 
-cells, Figure 7.  
Potentiation ranged from absent to pronounced within each of these libraries, 
revealing generally consistent SAR across all of the five ether-linked 
modifications held constant on the left-hand side of the structure.  From this, 
eleven compounds were selected for CRCs and foldshift assays based on 
degree of potentiation.  The associated SAR data for the chosen compounds 
from libraries 29-33 obtained from these assays are shown in Table 3. 
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Table 3.  SAR for select analogs from libraries 29-33 chosen based on an initial 
single-point potentiation screen at rM4
 
. 
 All compounds evaluated possessed an EC50 below 10 µM, except for 
31n, the di-flurobenzyl substituted 2-picolyl compound.  As found and discussed 
previously with regard to earlier libraries, foldshift did not track tightly with 
potency, as shown for example with 30h.  This t-butyl substituted morpholine 
analog had near 9 µM potency but caused a robust 62x foldshift of the ACh CRC.  
The dimethylpropyl analogs 29o displayed approximately 3 µM potency yet had 
only moderate ACh foldshift effects.  Interestingly, this dimethylpropylamine 
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motiety at R1 conferred poor potency (> 10 µM) in its parent compound 21b 
possessing the p-methoxybenzyl group at R2
 In general, di-fluorinated benzylic substitutions at R
, but the amide scan producing 
library 29a-p discovered side chains that rescued activity for this left-hand side 
modification. 
2 were favored, 
providing analogs with 2-5 µM range potencies and broad foldshift values.  The 
4-picolyl moieties of R1 with the 2,3-difluoro and 2,5-difluoro substitutions at R2
 
 of 
33n and 33o proved most desired when a balance of both potency and 
potentiation efficacy, consistent with previous SAR. 
Figure 7.  Single-point potentiator screen of libraries 29-33 in rM4-cells.  Test 
compound (fixed 10 µM) is added prior to addition of a submaximal (~EC20) 
concentration of Ach.  Intracellular Ca2+ mobilization is used as a functional 
readout for M4
 
 activation.  All data shown here represent the mean values from 
at least three experiments with similar results. 
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The morpholines at R1 of library 30a-r with bare alkyl and mono-oxygenated side 
chains at R2
 
 possessed strong foldshift effects despite moderately weaker 
potency compared with 31n and 33n.  The best lead compounds for this library 
are summarized in Figure 8. 
 
Figure 8.  Summary of second generation leads. 
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Figure 9.  The CRC for elevation of an ACh ~EC20
 
 and foldshift on a full ACh 
CRC for analogue 33n.  Interestingly, this 2,3-difluorobenzyl substituted 
analogue did not elevate the maximal response of ACh at the top of the CRC, 
which contrasts with 4-methoxybenzyl analogue 25k. 
Despite generation of a multidimensional library of analogues varying both 
sides of the lead scaffold, the approximately 400 nM potency (rat M4) of the first 
generation compounds 7o and 7p could not be improved upon despite retention 
of strong potentiation activity in terms of ACh CRC fold-shift (e.g. >50x).  Indeed, 
compounds 25k, 30b, and 33o each caused substantial leftward shift of ACh 
CRCs when applied at 30 µM, but were approximately an order of magnitude 
less potent than the first generation compounds at rat M4 receptor.  These SAR 
suggest the presence of a possible ~2 µM potency floor for this chemotype with 
6-position ether or amine modifications, as variation of the amide side chain 
failed to provide congers with EC50 values below this level.  In parallel, we 
evaluated the microsomal stability of 25k, 33n, 33o, and 30h in both rat and 
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human microsomes.  Replacement of the metabolically labile 6-methyl group with 
the ether linkage did indeed improve metabolic stability for all four analogues 
25k, 33n, 33o, and 30h (>90% parent remaining after 90 min) as compared to 7o 
and 7p (<10% parent remaining after 90 min).  Moreover, incorporation of the 
basic amine moieties in 25k, 33n, 33o, and 30h also improved solubility 
providing either homogeneous solutions or uniform microsuspensions, as the HCl 
salts at 10 mg mL -1, across a panel of pharmaceutically acceptable vehicles (β-
cyclodextrin, PEG400/H2O, etc.) relative to 7o and 7p, which were only soluble in 
10% Tween80.  In fact, 33n afforded a homogeneous solution at 15 mg/mL-1
Despite micromolar potency at rat M
 in 
pH 3 saline. 
4, we evaluated 25k, 33n, and 33o in 
our standard reversal of amphetamine-induced hyperlocomotion in vivo model, 
since a long-standing question in the PAM field has centered on whether EC50 or 
fold-shift is more relevant to provide in vivo efficacy (21).  Both 7o and 7p (EC50
 
 
values ~400 nM, fold-shifts of 30x and 70x, respectively) were efficacious in this 
model.  Interestingly, both 25k and 33o produced modest decreases in 
amphetamine-induced hyperlocomotion while 33n had no effect over the time 
course tested, Figure 10.  
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Figure 10. Modest reversal by 25k and 33o of amphetamine-induced 
hyperlocomotor activity in rats.  Rats were pretreated for 30 min with vehicle 
(10% Tween80 i.p., n=9; light circle and dark circle) or a 56.6 mgkg-1 dose of 
either 25k, 33n, or 33o i.p. (n=4), then given an injection of 1 mg/kg-1 s.c. 
amphetamine (indicated at t=0 min) except vehicle control, which was dosed with 
H2
 
O instead and locomotor activity was measured for an additional 60 min. The 
error bars represent the mean value plus or minus SEM. * denotes P<0.05 
versus vehicle plus amphetamine control group (dark circle). 
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These findings suggest that the diminished potency of these new 
compounds may have translated to reduced in vivo efficacy relative to 7o and 7p. 
Primarily, our efforts were aimed at exploring SAR at rat M4 and optimizing this 
series for beneficial DMPK and vehicle formulation properties for in vivo rodent 
behavioral studies.  While stability and physiochemical properties were improved, 
potency at rat M4 was diminished to a point where in vivo efficacy was reduced 
and, in the case of 33n, in vivo efficacy was lost.  However, rat and human 
mAChRs do diverge and species differences have been noted for other mAChR 
PAMs.  Therefore, we opted to evaluate representative compounds 25k, 33n, 
33o, and 30h in analogous functional cellbased Ca2+ assays using cells 
expressing the human M4 receptor (and promiscuous Gq15 for Ca2+ mobilization 
readout).  To this end, these four compounds were submitted to Millipore Corp. 
(St. Charles, USA) and assayed by their GPCR Profiler Service, which provided 
potency and ACh CRC fold-shift values with the human M4 receptor.  
Remarkably, each compound possessed EC50 values approximately in the 100–
200 nM range at human M4 Figure 11a, more than an order of magnitude 
greater potency than at the rat M4 receptor.  Each compound also elicited large 
leftward shifts of the control ACh CRC in human M4 cells Figure 11b similar to 
their respective fold-shifts at rat M4.  In contrast, the prototypical M4 PAMs 7o 
and 7p and about 20 other first generation analogues, displayed near equivalent 
EC50 values at rat and human M4, suggesting the basic residues in these newer 
analogue contact divergent residues in human M4
 
. 
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Figure 11.  Potentiation effects of 25k, 30h, 33n, and 33o in human M4/Gq15 
expressing cells by functional Ca2+
 
 mobilization assay. 
While receptor expression levels in the two cell lines is not known, ACh 
EC50 values in the two cell lines are equivalent (rat M4 ACh, EC50=154 nM; 
human M4 ACh, EC50=100 nM), and all first generation analogues were also 
equipotent.  These human M4 data exemplify the differences that may exist 
between species in terms of compound potency, efficacy, and other 
pharmacological parameters, despite relatively high structural similarity between 
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rat and human mAChRs.  In addition, 25k, 33n, 33o, and 30h and related second 
generation analogues remained highly M4 selective at both human and rat 
mAChR cell lines Figure 12.  Whereas a 30 µM concentration of 25k, 33n, 33o, 
and 30h afforded large leftward shifts (44–63x) of the ACh CRCs of M4, these 
same concentrations of compound had no effect on the ACh CRCs of M1, M2, M3 
or M5
 
 (data shown is for rat mAChRs). 
 
Figure 12.  Full concentration response curves for ACh in the absence and 
presence of a fixed 30 µM concentration of potentiators 25k, 30h, 33n, and 33o 
on M1, M2, M3, and M5
 
 cells. 
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Finally, while M1 PAMs and allosteric agonists have the potential to effect 
both the positive and cognitive symptom clusters of schizophrenia, M4 PAMs 
should only treat the positive symptoms (12-16).  Upon recognition that 
compounds 25k, 33n, 33o, and 30h possess the basic features of the refined H3 
pharmacophore model, Figure 13, we evaluated these compounds for their 
ability to function as H3
 
 antagonists and provide procognitive attributes (22, 23). 
 
Figure 13.  Refined H3 pharmacophore model and alignment with M4
 
 PAM 33n. 
Compounds 25k, 33o and 30h were found to inhibit human H3 with IC50 
values of ~10 µM, while 33n afforded an IC50 value of 6.3 µM.  While weak, this 
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result suggests that it is possible to “dial in” H3 antagonist activity into this new 
series of M4 PAMs, and future efforts will focus on optimizing compounds with 
comparable M4 PAM and H3 antagonist activity for the treatment of the positive 
and cognitive symptom clusters of schizophrenia.  In summary, a lead 
optimization campaign around VU0010010, 1, furnished M4 PAMs 7o and 7p, 
elaborating on these compounds provided novel analogues with improved 
metabolic stability and physiochemical properties, but diminished efficacy at rat 
M4 (EC50 values ~2 µM) while retaining comparable foldshift (14–67x) of the ACh 
CRC.  Moreover, though weak at rat M4, several analogues displayed modest in 
vivo efficacy in reversing amphetamine-induced hyperlocomotion, a classic 
preclinical antipsychotic model.  Surprisingly, we noted significant species 
differences within this new series of M4 PAMs, where analogues such as 33n 
displayed an order of magnitude greater potency at human M4 (EC50=95 nM) 
than at the rat M4 receptor (EC50=2.4 µM) with comparable fold-shifts (human, 
60x; rat, 44x) and high M4 mAChR subtype selectivity.  To further expand the 
therapeutic relevance of these new M4 PAMs for the treatment of schizophrenia 
beyond the positive symptom cluster, we evaluated analogues against the H3 
receptor as they align well with the refined H3 pharmacophore model.  M4 PAM 
33n was found to provide modest inhibition of H3 with an IC50 value of 6.3 µM, 
suggesting that it might be possible to develop analogues with dual M4 PAM and 
H3
 
 antagonist activity to effectively treat both the positive and cognitive symptom 
clusters of schizophrenia. 
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 M4
 
 Experimental Section- 
 
Synthesis of 3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno[2,3-
b]pyridine-2-carboxamide, VU0152100, 3: 
The following components were added to a stirred solution of 3-amino-4,6-
dimethylthioenol[2,3-b]-pyridine-2-carboxylic acid (2.50 g, 11.26 mmol; 
ChemBridge Corporation) in CH2Cl2 (90 mL) at 25°C under room atmosphere: 
N,N-diisopropylethylamine (10 mL, 56.66 mmol); 1-hydroxybenzotriazole hydrate 
(1.52 g, 11.26 mmol, 1.0 equivalents); piperonylamine (1.87 g, 12.38 mmol, 1.1 
equivalents); and N-(3-dimethylaminopropyl)-N’-ethyl-carbodiimide hydrochloride 
(4.32 g, 22.52 mmol, 2 equivalents).  After 48 h, macroporous triethylammonium 
methylpolystyrene carbonate (3.66 g, 11.26 mmol, 3.077 mmol/g, 1.0 
equivalents) was added to the solution, which was then stirred for 3 h at 25 °C 
under room atmosphere.  The solution was vacuum-filtered next, and the filtrate 
was separated with citric acid (1.0 M in water) and CH2Cl2. The organics were 
dried over MgSO4 and concentrated in vacuo to produce a dark yellow solid.  
The solid was purified by column chromatography (silica gel, fixed 1:2 
EtOAc/hexanes) to afford 2.0 g (5.63 mmol, 50%) of the title compound 3 as a 
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yellow solid.  Analytical LC/MS (J-Sphere80-S4, 3.0 X 50 mm, 4.0 min gradient, 
5%[CH3CN]: 95%[0.1% trifluoroacetic acid/H2O] to 100%[CH3CN]): 2.740 min, 
99% (214 nm and ELSD), M + 1 peak m/e 356.10; 1H NMR (400 MHz, DMSO-
d6) δ = 8.38 (s, 1H), 7.18 (s, 1H), 6.88 (s, 1H), 6.84 (d, J = 8.0 Hz, 1H), 6.78 (d, J 
= 8.0 Hz, 1H), 5.98 (br s, 2H), 5.97 (s, 2H), 4.30 (d, J = 5.2 Hz, 2H), 2.77 (s, 3H), 
2.57 (s, 3H);  13CNMR (100 MHz, DMSO-d6) δ = 179.9, 164.8, 161.7, 158.0, 
153.4, 147.4, 133.8, 122.4, 121.9, 120.5, 108.0, 107.9, 100.8, 92.8, 42.1, 22.4, 
20.0; high-resolution mass spectroscopy (Q-ToF): m/z calc for C18H17N3O3
 
S [M 
+ H]: 356.0991; found, 356.1069. 
 
6-amino-2-mercapto-4-methylnicotinonitrile 18:   
To five 20 mL microwave vials containing 2-cyanothioacetamide (0.01 mol) each 
was added 3-aminocrotonitrile (0.01 mol) and then EtOH (10 mL).  Once 
dissolved pyridine (0.05 mol) was added and the vial was capped.  The reaction 
mixtures were heated to 160 oC for 12 min. consecutively.  The crude reaction 
mixtures were combined and concentrated to a reddish oil.  To this was added 
MeOH (150 mL) and heated to reflux, upon cooling an orange solid crashed out 
which was filtered and washed with ether to afford 3.47g of pure (6) (42%).   1H 
NMR (400MHz, DMSO-d6): δ = 7.20 (br s, 2H), 5.90 (s, 1H), 2.2 (s, 3H).  13C 
 95 
(100MHz, DMSO-d6): d= 175.3, 155.1, 153.5, 118.0, 100.2, 98.9, 20.8. HRMS 
calcd for C7H7N3
 
S [M + H] 166.0435; found 166.0439. 
 
3,6-diamino-N-(4-methoxybenzyl)-4-methylthieno[2,3-b]pyridine-2-
carboxamide 20:   
To a 20 mL microwave vial containing 18 (3.0 mmol) was added K2CO3 (6 
mmol), and DMF (10 mL).  To this solution was added solid 19 then capped, and 
heated to 160 oC for 10 min.  Once complete the reaction was partitioned 
between H2O (100 mL) and DCM (100 mL), separated, and the aqueous layer 
extracted 2x with DCM (100 mL).  The organic layer was dried with solid MgSO4, 
filtered, and concentrated to a light brown solid.  This solid was crystallized in 
EtOAc and Hexanes and filtered to obtain 0.8g of pure 20 as a light yellow solid 
(75%).   1H NMR (400MHz, DMSO-d6): δ = 8.41 (s, 1H), 7.13 (d, J = 8.8Hz, 2H), 
6.98 (br s, 2H), 6.83 (d, J = 8.4 Hz, 2H), 6.12 (s, 1H), 3.89 (s, 2H), 3.72 (s, 3H), 
2.22 (s, 3H).  13C (100MHz, DMSO-d6): δ = 167.4, 160.8, 160.1, 158.1, 151.0, 
131.1, 128.3, 116.7, 113.7, 103.9, 55.0, 41.9, 32.8, 19.6. HRMS calcd for 
C17H18N4O2S [M + H] 343.1222; found 343.1229.         
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Alkylamine Library (21a-p) General Procedure:   
To a 5 mL microwave vial containing 20 (0.073 mmol), was added Cs2CO3 (0.21 
mmol), KI (0.073 mmol), R1-Cl (0.080 mmol), and DMF (3 mL).  The reaction was 
stirred 5 min. to eliminate CO2, capped, and heated to 160 oC for 30 min.  Once 
complete the reaction was partitioned between H2
 
O (5 mL), and DCM (5 mL), 
separated via a 12 mL IST phase separator, concentrated and purified by mass 
directed HPLC to furnish 21a-p (15-80%). 
 
Alkylether Library (25a-s) General Procedure:   
To a 5 mL microwave vial containing 24 (0.146 mmol), was added Cs2CO3 
(0.438 mmol), KI (0.291 mmol), R1-Cl (0.219 mmol), and DMF (3 mL).  The 
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reaction was stirred 5 min. to eliminate CO2, capped, and heated to 160 oC for 30 
min.  Once complete the reaction was partitioned between H2
 
O (5 mL), and DCM 
(5 mL), separated via a 12 mL IST phase separator, concentrated and purified by 
mass directed HPLC to furnish 25a-s (15-80%). 
 
2-mercapto-4-methyl-6-oxo-1,6-dihydropyridine-3-carbonitrile 23:   
1H NMR (400MHz, DMSO-d6): δ = 10.40 (br s, 1H), 8.67 (br s, 1H), 5.38 (s, 1H), 
1.99 (s, 3H).  13C (100MHz, DMSO-d6): δ = 176.3, 162.4, 151.0, 120.7, 106.8, 
92.7, 20.5.  HRMS calcd for C7H6N2
 
OS [M + H] 167.0277; found 167.0279. 
 
ethyl 3-amino-4-methyl-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-
carboxylate 27:   
1H NMR (400MHz, DMSO-d6); δ = 6.42 (s, 1H), 4.12 (m, 4H), 2.34 (s, 3H), 1.18 
(t, J = 7.2 Hz, 3H). 13C (100MHz, DMSO-d6): δ = 168.3, 164.8, 160.0, 154.5, 
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115.5, 106.8, 97.8, 59.9, 19.7, 13.9.  HRMS calcd for C11H13N2O3
 
S [M + H] 
253.0647, found 253.0644. 
 
Alkyl Pyridone Ethyl Ester (28a-e) General Procedure:   
To a 20 mL microwave vial containing 27 (0.04 mol), was added Cs2CO3 (0.012 
mol), KI (0.008 mol), R1-Cl (0.0044 mmol), and DMF (10 mL).  The reaction was 
stirred 5 min. to eliminate CO2, capped, and heated to 160 oC for 30 min.  Once 
complete the reaction was partitioned between H2O (50 mL), and DCM (50 mL), 
separated, and the aqueous extracted 1x with DCM (50 mL).  The organic layer 
was dried with MgSO4, filtered and concentrated.  The resulting material was 
added to a 10g 60CC SCX cartridge and washed with 3 column volumes of 
MeOH.  The product was then eluted with 2 column volumes of 2M NH3
 
 in MeOH 
to provide pure 28a-e (75-95%). 
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ethyl 3-amino-6-(3-(dimethylamino)propoxy)-4-methylthieno[2,3-b]pyridine-
2-carboxylate 28a:   
1H NMR (400MHz, DMSO-d6); δ = 6.72 (s, 2H), 6.57 (s, 1H), 4.25 (m, 4H), 2.66 
(s, 3H), 2.37 (t, J = 7.2 Hz, 2H), 2.16 (s, 6H), 1.84 (m, 2H), 1.27 (t, J = 6.8 Hz, 
3H). 13C (100MHz, DMSO-d6): δ = 164.7, 163.8, 159.3, 150.3, 147.6, 119.1, 
109.5, 64.5, 59.7, 55.5, 44.9, 26.3, 19.8, 14.4. HRMS calcd for C16H24N3O3
 
S [M 
+ H] 338.1538, found 338.1527. 
 
ethyl 3-amino-4-methyl-6-(2-morpholinoethoxy)thieno[2,3-b]pyridine-2-
carboxylate 28b:   
1H NMR (400MHz, DMSO-d6); δ = 6.76 (s, 2H), 6.65 (s, 1H), 4.57 (br s, 2H), 4.24 
(q, J = 14.4, 7.2 Hz, 2H), 3.72 (br s, 4H), 3.20 (br s, 6H), 2.70 (s, 3H), 1.27 (t, J = 
6.8 Hz, 3H).  13C (100MHz, DMSO-d6): δ = 164.7, 163.1, 159.0, 150.3, 148.1, 
119.6, 118.7, 115.7, 109.6, 64.3, 59.8, 55.5, 52.3, 19.9, 14.4.  HRMS calcd for 
C17H24N3O4S [M + H] 366.1488, found 366.1476. 
 100 
 
 
ethyl 3-amino-4-methyl-6-(pyridin-2-ylmethoxy)thieno[2,3-b]pyridine-2-
carboxylate 28c:   
1H NMR (400MHz, DMSO-d6); δ = 8.55 (d, J = 4.4 Hz, 1H), 7.80, (t, J = 8.0 Hz, 
1H), 7.46 (d, J = 8.0 Hz, 1H), 7.33 (t, J = 6 Hz, 1H), 6.74 (s, 2H), 6.73 (s, 1H), 
5.45 (s, 2H), 4.23 (q, J = 14.0, 7.2 Hz, 2H), 2.70 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H).   
13C (100MHz, DMSO-d6): δ = 164.7, 163.3, 159.0, 156.3, 150.2, 149.1, 148.1, 
136.8, 122.9, 121.7, 119.6, 109.6, 68.1, 59.8, 19.9, 14.4.   HRMS calcd for 
C17H18N3O3
 
S [M + H] 344.1069, found 344.1057. 
 
ethyl 3-amino-4-methyl-6-(pyridin-3-ylmethoxy)thieno[2,3-b]pyridine-2-
carboxylate 28d:   
1H NMR (400MHz, DMSO-d6); δ = 8.70 (s, 1H), 8.54 (d, J = 4.8 Hz, 1H), 7.89 (d, 
J = 8.0 Hz, 1H), 7.42 (t, J = 4.8 Hz, 1H), 6.75 (s, 2H), 6.97 (s, 1H), 5.42 (s, 2H), 
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4.24 (q, J = 14.4, 7.2 Hz, 2H), 2.69 (s, 3H), 1.28 (t, J = 6.8 Hz, 3H).  13C 
(100MHz, DMSO-d6): δ = 164.7, 163.3, 159.0, 150.3, 149.4, 149.1, 148.1, 136.1, 
132.3, 123.5, 119.6, 109.6, 65.3, 59.8, 19.9, 14.4.  HRMS calcd for C17H18N-
3O3
 
S [M + H] 344.1069, found 344.1064. 
 
ethyl 3-amino-4-methyl-6-(pyridin-4-ylmethoxy)thieno[2,3-b]pyridine-2-
carboxylate 28e:   
1H NMR (400MHz, DMSO-d6); δ = 8.56 (d, J = 6.0 Hz, 2H), 7.45 (d, J = 6.0 Hz, 
2H), 6.77 (s, 1H), 6.75 (s, 2H), 5.45 (s, 2H), 4.24 (q, J = 14.0, 6.8 Hz, 2H), 2.71 
(s, 3H), 1.27 (t, J = 7.2 Hz, 3H).  13C (100MHz, DMSO-d6): δ = 164.6, 163.1, 
159.0, 150.2, 149.6, 148.3, 145.9, 122.0, 109.6, 65.7, 59.8, 19.9, 14.4.  HRMS 
calcd for C17H18N3O3
 
S [M + H] 344.1069, found 344.1057. 
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3-amino-N-(4-methoxybenzyl)-4-methyl-6-(pyridin-4-ylmethoxy)thieno[2,3-
b]pyridine-2-carboxamide dihydrochloride 25k:  1H NMR (400MHz, DMSO-
d6): δ = 8.90 (d, J = 6.4 Hz, 2H), 8.14 (t, J = 5.6 Hz, 1H), 8.05 (d, J = 6.4 Hz, 2H), 
7.22 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 6.84 (s, 1H), 5.73 (s, 2H), 4.32 
(d, J = 5.6 Hz, 2H), 3.72 (s, 3H), 2.74 (s, 3H). ).  13C (100MHz, DMSO-d6): δ = 
165.0, 162.0, 158.1, 156.9, 148.1, 147.9, 142.2, 132.0, 129.3, 128.5, 124.1, 
121.0, 115.1, 113.6, 109.4, 65.3, 55.0, 41.6, 19.9. HRMS calcd for C23H23N4O3
 
S 
[M + H] 435.1491, found 435.1490. 
 
3-amino-N-(2,3-difluorobenzyl)-4-methyl-6-(pyridin-4-ylmethoxy)thieno[2,3-
b]pyridine-2-carboxamide dihydrochloride 33n:  1H NMR (400MHz, DMSO-
d6): δ = 8.92 (d, J = 6.8 Hz, 2H), 8.30 (t, J = 5.6 Hz, 1H), 8.09 (d, J = 6.4 Hz, 2H), 
7.32 (m, 1H), 7.16 (m, 2H), 6.85 (s, 1H), 5.75 (s, 2H), 4.46 (d, J = 5.6 Hz, 2H), 
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2.74 (s, 3H).  13C (100MHz, DMSO-d6): δ = 165.2, 162.1, 157.8, 157.0, 150.8, 
148.8, 148.3, 148.1, 146.4, 146.2, 141.4, 129.3 (d, J = 11.0 hz), 124.5, 124.3, 
120.9, 115.6 (d, J = 17.0 Hz), 109.5, 65.3, 35.7, 19.9.  HRMS calcd for C22H19N-
4O2F2
 
S [M + H] 441.1197, found 441.1196. 
 
3-amino-N-(2,5-difluorobenzyl)-4-methyl-6-(pyridin-4-ylmethoxy)thieno[2,3-
b]pyridine-2-carboxamide dihydrochloride 33o:  1H NMR (400MHz, DMSO-
d6): δ = 8.57 (d, J = 6.0 Hz, 2H), 8.19 (t, J = 5.6 Hz, 1H), 7.44 (d, J = 6.0 Hz, 2H), 
7.24 (m, 1H), 7.10 (m, 2H), 6.77 (br s, 2H), 6.77 (s, 1H), 5.46 (s, 2H), 4.43 (d, J = 
5.6 Hz, 2H), 2.72 (s, 3H). ).  13C (100MHz, DMSO-d6): δ = 165.3, 162.7, 159.3, 
157.2, 156.9, 154.7, 149.6, 148.4, 147.9, 146.0, 128.8 (dd, J = 7.0, 17.0 Hz), 
121.9, 120.6, 116.6 (dd, J = 8.0, 24.0 Hz), 115.2 (dd, J = 5.0, 25.0 Hz), 114.9 
(dd, J = 8.0, 24.0 Hz), 109.6, 65.7, 35.9, 19.9.   HRMS calcd for C22H19N4O2F2
 
S 
[M + H] 441.1197, found 441.1194. 
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3-amino-N-tert-butyl-4-methyl-6-(2-morpholinoethoxy)thieno[2,3-b]pyridine-
2-carboxamide dihydrochloride 30h:  1H NMR (400MHz, DMSO-d6): δ = 6.65 
(s, 1H), 6.62 (s, 1H), 6.31 (br s, 3H), 4.71 (t, J = 4.8 Hz, 2H), 3.87 (m, 4H), 3.50 
(m, 4H), 3.17 (m, 2H), 2.70 (s, 3H), 1.36 (s, 9H).  13C (100MHz, DMSO-d6): δ = 
165.3, 162.2, 162.1, 156.6, 147.6, 147.1, 120.9, 109.5, 62.0, 60.5, 54.7, 51.6, 
51.2, 28.8, 19.9.  HRMS calcd for C19H29N4O3
 
S [M + H] 393.1960, found 
393.1958. 
 
Cell Culture:   
All recombinant CHO cell lines used were previously described (13, 15).  CHO 
cells stably expressing rat M1, human M3, or human M5 were plated at a seeding 
density of 50,000 cells/100mL/well.  CHO cells stably co-expressing human 
M2/Gqi5 and rat M4/Gqi5 were plated at a seeding density of 60,000 
cells/100mL/well.  For calcium mobilization assays, cells were incubated in 
antibiotic-free medium overnight at 37 °C/5% CO2 
 
and assayed the following day. 
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Calcium Mobilization Assay:  
All calcium mobilization assays were performed similar to those previously 
described (13,15).  Cells were loaded with calcium indicator dye (Fluo-4 AM, 
2µM) for 60 min at 37 °C.  Dye was removed and replaced with the appropriate 
volume of assay buffer, pH 7.4 (1X HBSS (Hanks’ Balanced Salt Solution), 
supplemented with 20 mM HEPES and 2.5 mM probenecid).  All compounds 
were serially diluted in assay buffer for a final 2X stock in 0.6% DMSO.  This 
stock was then added to the assay plate for a final DMSO concentration of 0.3%.  
Acetylcholine (~EC20 concentration or full dose-response curve) was prepared at 
a 10X stock solution in assay buffer prior to addition to assay plates.  Calcium 
mobilization was measured at 25 °C using a FLEXstation II (Molecular Devices, 
Sunnyvale, CA).  Cells were preincubated with test compound (or vehicle) for 1.5 
min prior to the addition of the agonist, acetylcholine.  Cells were then stimulated 
for 50 sec with a submaximal concentration (EC20
 
) or a full dose-response curve 
of acetylcholine.  The signal amplitude was first normalized to baseline and then 
as a percentage of the maximal response to acetylcholine; plotted data and 
pharmacological parameters were obtained using GraphPad Prism (v4.0c) 
software.  Indicated data values represent means from at least three experiments 
with similar results. 
 
 106 
References 
1. Lindsley, C.W.; Wisnoski, D.D.; Leister, W.H.; O’Brien, J.A.; Lemaire, W.; 
Williams, D.L. Jr.; Burno, M.; Sur, C.; Kinney, G.G.; Pettibone, D.J. et al. J. Med. 
Chem., 2004, 47, 5825–5828. 
2. Zhao, Z.; Wisnoski, D.D.; O’Brien, J.A.; Lemaire, W.; Williams, D.L. Jr.; 
Jacobson, M.A.; Wittman, M.; Ha, S.N.; Schaffhauser, H.; Sur, C. et al. Bioorg. 
Med. Chem. Lett. 2007, 1, 1386–1391. 
3. Shirey, J.K.; Xiang, Z.; Orton, D.; Brady, A.E.; Johnson, K.A.; Williams, R.; 
Ayala, J.E.; Rodriguez, A.L.; Wess, J.; Weaver, D. et al. Nat. Chem. Biol., 2008, 
4, 42–50. 
4. Bonner, T. I.; Buckley, N. J.; Young, A. C.; Brann, M. R. Science, 1987, 
237:4814, 527-532. 
5. Bonner, T. I. ; Young, A. C.; Brann, M. R.; Buckley, N. J. Neuron, 1988, 
1:5, 403-410. 
6. Caulfield, M. P.; Pharmacol, Ther.,1993, 58(3), 319-379. 
7. Bymaster, F. P.; McKinzie, D. L.; Felder, C. C.; Wess, J. Neurochem. 
Res., 2003, 28(3-4), 437-442. 
8. Wess, J.; Duttaroy, A.; Zhang, W.; Gomeza, J.; Cui, Y.; Miyakawa, T.; 
Bymaster, F. P.; McKinzie, L.; Felder, C. C.; Lamping, K. G.; Faraci, F. M.; Deng, 
C.; Yamada, M. Receptors Channels, 2003, 9(4), 279-290. 
 107 
9. Clader, J. W.; Wang, Y.; Curr. Pharm. Des. 2005, 11(26), 3353-3361. 
10. Langmead, C. J.; Watson, J.; Reavill, C. Pharmacol. Ther. 2008, 117(2), 
232-243. 
11. Wess, J.; Eglen, R. M.; Gautam, D.; Nat. Rev. Drug Discov., 2007, 6(9), 
721-733. 
12. Felder, C. C.; Bymaster, F. P.; Ward, J.; DeLapp, N.; J. Med. Chem. 2000, 
43(23), 4333-4353. 
13. Brady, A. E.; Jones, C. K.; Bridges, T. M.; Kennedy, J. P.; Thompson, A. 
D.; Heiman, J. U.; Breininger, M. L.; Gentry, P. R.; Yin, H.; Jadhav, S. B.; Shirey, 
J. K.; Conn, P. J.; Lindsley, C. W.; J. Pharmacol. Exp. Ther. 2008, 327(3), 941-
953. 
14. Jones, C. K.; Brady, A. E.; Davis, A. A.; Xiang, Z.; Bubser, M.; Tantawy, 
M. N.; Kane, A. S.; Bridges, T. M.; Kennedy, J. P.; Bradley, S. R.; Peterson, T. 
E.; Ansari, M. S.; Baldwin, R. M.; Kessler, R. M.; Deutch, A. Y.; Lah, J. J.; Levey, 
A. I.; Lindsley, C. W.; Conn, P. J.; J. Neurosci. 2008, 28(41), 10422-10433. 
15. Shirey, J. K.; Xiang, Z.; Orton, D.; Brady, A. E.; Johnson, K. A.; Williams, 
R.; Ayala, J. E.; Rodriguez, A. L.; Wess, J.; Weaver, D.; Niswender, C. M.; Conn, 
P. J.; Nat. Chem. Biol. 2008, 4(1), 42-50. 
16. Langmead, C. J.; Austin, N. E.; Branch, C. L.; Brown, J. T.; Buchanan, K. 
A.; Davies, C. H.; Forbes, I. T.; Fry, V. A.; Hagan, J. J.; Herdon, H. J.; Jones, G. 
A.; Jeggo, R.; Kew, J. N.; Mazzali, A.; Melarange, R.; Patel, N.; Pardoe, J.; 
 108 
Randall, A. D.; Roberts, C.; Roopun, A.; Starr, K. R.; Teriakidis, A.; Wood, M. D.; 
Whittington, M.; Wu, Z.; Watson, J.;  J. Pharmacol. 2008, 154(5), 1104-1115. 
17. Spalding, T. A.; Trotter, C.; Skjaerbaek, N.; Messier, T. L.; Currier, E. A.; 
Burstein, E. S.; Li, D.; Hacksell, U.; Brann, M. R.; Mol. Pharmacol. 2002, 61(6), 
1297-1302. 
18. Bridges, T. M.; Lindsley, C. W.; ACS Chem. Biol. 2008, 3(9), 530-541. 
19. F. A. H. Abu-Shanab, A.; Gaber, H.; Mousa, Sayed A. S. Journal of Sulfur 
Chemistry, 2006, 27(4), 293-305. 
20. Litvinov, V. P. S.; Yu. A.; Promonenkov, V. K.; Rodinovskaya, L. A.; 
Shestopalov, A. M.; Mortikov, V. Yu. Seriya Khimicheskaya, 1984, 8, 1869-1870. 
21. Conn, P. J.; Christopolous, A.; Lindsley, C. W. Nat. Rev. Drug Discovery, 
2009, 8, 41–54. 
 
22. Celanire, S.; Wijtmans, M.; Talaga, P.; Leurs, R.; de Esch, J. P. Drug 
Discovery Today, 2005, 10, 1613–1627. 
23. Esbenshade, T. A.; Brownman, K. E.; Bitner, R. S.; Strakhova, M.; Cowart, 
M. D.; Brioni, J. D. J. Pharmacol., 2008, 154, 1166–1181. 
24. Yasuta, R.P.; Ciesla, W.; Flores, L.R.; Wall, S.J.; et al. Mol. Pharmacol. 
1993, 43, 149-157. 
25. Wirtshafter, D.; Osbron, C.V. J. Chem. Neuroanat. 2004, 28, 107-116. 
 109 
26. Tzavara, E.T.; Bymaster, F.P.; Davis, R.J.; et al. FASEB J. 2004, 18, 
1410-1412. 
27. Wess, J.; Eglen, R. M.; Guatam, D. Nat. Rev. Drug Disc. 2007, 6, 721-
733. 
28. Bridges, T. M.; LeBois, E. P.; Hopkins, C. R.; Wood, M. R.; Jones, C. K.; 
Conn, P. J.; Lindsley, C. W. Drug News Perspect. 2010, 23, 229-240. 
29. Vilaro, M.T.; Palacios, J.M.; Mengod, G. Neurosci. Lett. 1990, 114, 154-
159. 
30 Bodick, N.C.; Offen, W.W.; Levey, A.I.; Cutler, N.R.; Gauthier, S.G.; Satlin, 
A.; Shannon, H.E.; Tollefson, G.D.; Rasmussen, K.; Bymaster, F.P. et al. Arch. 
Neurol. 1997, 54, 465-473. 
31. Shekhar, A.; Potter, W.Z.; Lightfoot, J.; Lienemann, J.; Dube´, S.; 
Mallinckrodt, C.; Bymaster, F.P.; McKinzie, D.L.; Felder, C.C. Am. J. Psychiatry. 
2008, 165, 1033-1039. 
32. All tables and portions of text previously published are used with consent 
from the publisher. 
 110 
Chapter III 
 
EXPLORATION OF THE SYNTHESIS OF PIPERAZIMYCIN A 
 
Fenical and co-workers recently reported on the isolation of piperazimycin 
A 1 from the fermentation broth of a Streptomyces sp., cultivated from marine 
sediments near the island of Guam (1).  A cyclic hexadepsipeptide, 1 is 
composed of rare amino acids such as hydroxyacetic acid (HAA), α-
methylserine, a novel (S)-2-amino-8-methyl-4,6-nonadecadienoic acid (AMNA), 
two γ-hydroxypiperazic acids (S,S)-γOHPip1 and (R,R)-γOHPip2 and one γ-
chloropiperazic acid (R,S)-γClPip, Figure 1 (1). 
 
 
Figure 1.  Structure of Piperazimycin A, 1. 
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Piperazimycin A, 1, proved to be a potent cancer cell cytotoxin which exhibited in 
vitro cytotoxicity toward multiple tumor cell lines with a mean GI50 of 100 nM (1).   
Based on its novel molecular architecture, the diversity of non-proteogenic amino 
acid building blocks and its potent cytotoxicity, we embarked on a total synthesis 
campaign aimed at delivering piperazimycin A, 1 in sufficient quantities to 
elucidate the molecular target(s) responsible for the biological activity. 
 The retrosythesis of Piperazimycin A, 1 was planned according to the 
individual unnatural amino acids present in the parent structure, Figure 2. 
 
 
Figure 2.  Structures of the individual components of Piperazimycin A, 1. 
 
The envisioned synthetic plan would be to make all of the individual components 
of Piperazimycin A, 1, and join these individual components utilizing traditional 
peptide coupling methodology. 
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Figure 3.  γ-functionalized piperazic acid target molecules 2-4. 
 
In order to complete a total synthesis of 1, we first had to synthesize the 
requisite γ-functionalized piperazic acids 2-4, Figure 3.  Upon examination of the 
literature, we were surprised that there are very few synthetic routes to these 
unnatural amino acids, especially with mono-N-protection (2-8).  A single report 
by Hamada and co-workers demonstrated that the mono-N-Boc analogues 2 and 
3 could be accessed, which we desired for the sequence of peptide couplings en 
route to 1 (2).  In accord with a report from Hale and co-workers (7), we 
anticipated that deprotection of the TBS group of 3 and exposure to PPh3 and 
MeCN-CCl4 would install the chlorine with inversion providing the corresponding 
γ-ClPip 4; however, this step had never been performed on a mono-N-protected 
piperazic acid (3,7). 
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Scheme 1.  Piperazic acid synthesis utilizing the Hamada methodology. 
 
Hamada’s protocol begins with (R)-4-chloro-3-hydroxybutanoic acid ethyl 
ester 5 which is O-TBS protected to give protected alcohol 6, in 98% yield.  6 is 
then reduced with DIBAL-H in hexanes to deliver aldehyde 7 in 77% yield 
Scheme 1 (2).  Exposure of 7 to hydrazine hydrate in EtOH for 16 hours afforded 
the cyclic hydrazone 7, which was then mono-N-benzylated to provide 8 in 89% 
yield over 2 steps.  A Lewis acid-promoted Strecker reaction with stoichiometric 
Zn(OTf)2 results in an 81:19 ratio of diastereomers in favor of the cis adduct 10, 
which can be easily separated by column chromatography.  Deprotection and 
hydrolysis with 6 N HCl at reflux for 12 hours under argon led to 12 which is then 
esterified 13 with catalytic TsOH in refluxing methanol for 19 hours.  Finally, 13 is 
selectively mono-Boc protected at the N1 position by treatment with Boc2O in 1:1 
dioxane:water for 46 hours to deliver 14, two steps away from (R,R)-γOHPip2 4 
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(2).  Moreover, the analogous precursor to (S,S)-γOHPip1 3 could also be 
accessed via this route by starting the sequence with (S)-4-chloro-3-
hydroxybutanoic acid ethyl ester in place of 5.  While this was an attractive route, 
we felt there was room to optimize throughout this synthesis, as many steps 
required long reaction times (12-46 hours) (2).   
 
 
Scheme 2.  Optimized Hamada route to piperazic acids. 
 
Our modified Hamada protocol employed microwave-assisted organic 
synthesis (MAOS) to dramatically reduce reaction times for four key steps (9, 
10).   As shown in Scheme 2, the changes to the original protocol are highlighted 
in red.  In our hands, (R)-4-chloro-3-hydroxybutanoic acid ethyl ester 5 is 
silylated and reduced with DIBAL-H in toluene, in place of hexanes, to deliver 
aldehyde 7 in an improved yield of 91% for the reduction.  An MAOS 
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condensation of 7 with hydrazine provides the cyclic hydrazone 8 in only 20 
minutes (versus 16 h), which is then mono-N-benzylated under microwave 
irradition (120 oC, 20 min) to provide 9 in 90% yield over 2 steps.   The key 
Strecker reaction was performed as prescibed and delivered an 81:19 ratio in 
favor of desired compound 10, which was separated by flash column 
chromatography from its diasteriomer to afford a 57% yield of the cis 
diastereomer 10.  Although attempts were made to reduce the reaction time for 
the asymmetric Strecker reaction, any microwave irradiation only led to 
decomposition.  Deprotection and saponification with 6 N HCl in the microwave 
(120 oC, 10 min) delivers 11, which is then subjected to another MAOS reaction 
(120 oC, 30 min) with cat. TsOH in MeOH to provide ester 12 in 75% yield for the 
two steps.  At this point, the modified reaction protocol reduced total reaction 
time for the synthesis dramatically and provided improvements in the overall yield 
on a multi-gram scale.   Specifically, the reaction times for the synthesis of 8, 9, 
11 and 12 were reduced from 49 hours to only 80 minutes (a ~40-fold reduction) 
by virtue of microwave irradiation. 
However, we were unable to access the mono-N-Boc derivative 13 in 
reasonable yield.   While we could prepare 13 on an ~25 mg scale in yields 
ranging from 5-25%, the reaction failed on a larger, synthetically useful scale en 
route to the total synthesis of piperazimycin A, 1.  Revisiting Hamada’s paper 
indicated that they only prepared 13 on a <30 mg scale, and did not perform the 
reaction on larger scale (2).  We explored alternative protocols (MAOS and 
conventional) and alternative reagents for formation of the t-butyl carbamate, but 
 116 
all attempts provided very little conversion to 13.  Danishefsky and co-workers 
previously demonstrated that the analogous Teoc derivative of 13 could be 
prepared on a large scale, however we decided to attempt this route using an 
alloc protecting group (4-6). 
 
 
Scheme 3.  Synthesis of Alloc protected piperazic acids. 
 
After many unsuccessful attempts, we developed a high-yielding route to 
an Alloc-protected congener of 13 as our modified MAOS-route to 12 worked well 
on multi-gram scale.  As shown in Scheme 3, addition of Alloc-Cl to 12 at 0 oC in 
pyridine, then exposing to microwave irradiation for 10 minutes at 120oC provides 
the previously undescribed N-Alloc congener (R,R)-14 in 74% yield.  Another 
MAOS mediated silylation provided 15 in 81% yield, followed by a saponification 
step to deliver the key N-Alloc-(R,R)-γ-OTBSPip2 16 in quantitative yield which 
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was used in further couplings without purification.  Following Scheme 2, but 
substituting the (R)-4-chloro-3-hydroxybutanoic acid ethyl ester 5 with the 
corresponding (S)-enantiomer 17 provides 18 in equivalent yield and 
diastereomeric ratio as 9, Scheme 4.  Deprotection and hydrolysis with 6 N HCl 
in the microwave (120 oC, 10 min) delivers 19, which is then subjected to another 
MAOS reaction (120 oC, 30 min) with cat.  TsOH in MeOH to provide ester 20.  
Finally, 20 is selectively mono-Alloc protected at the N1 position by treatment 
with Alloc-Cl in pyridine at 0 oC and then irradiated in the microwave for 10 
minutes at 120 oC provides the previously undescribed N-Alloc congener (S,S)-
21 in 75% yield for the three steps.  Another MAOS mediated silylation provided 
22 in 83% yield, followed by a saponification step to deliver the key N-Alloc-
(S,S)-γ-OTBSPip1 23 in quantitative yield. 
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Scheme 4.  Synthesis of (S,S)-γ-OTBSPip1 22. 
 
 
Scheme 5.  Synthesis of (R,S)-γ-Cl Pip 26. 
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With two of the three requisite piperazic acids in hand, effort now focused 
on preparing the remaining N-Alloc analogue of target molecule (R,S)-γ-ClPip  
26.  As shown in Scheme 5, the application of the Hale protocol (7), using PPh3, 
MeCN:CCl4 1:1, employing (R,R)-14 provided (R,S)-24 in 40% isolated yield 
along with a 20% yield of the elimination product 25.   We were pleased to see 
that the first application of the Hale protocol (7) with a mono-N-protected 
substrate provided an equivalent yield to the di-N-protected piperazic acids 
without greater propensity for elimination to form 25.  With 24 in hand, mild 
saponification conditions delivered previously unknown N-Alloc-(R,S)-γ-ClPip 26 
in 89% yield. 
At this point in the synthesis of the piperazic acids of piperazamycin A we 
have modified Hamada’s original approach and developed an accelerated, high 
yielding protocol, taking advantage of the power of MAOS, for the synthesis of γ-
functionalized piperazic acids.   We have also demonstrated that selective mono-
Boc protection at the N1 position of piperazic acids is a poor reaction that 
proceeds only on small scale.  Importantly, we have developed a scalable MAOS 
protocol for selective Alloc protection at the N1 position of functionalized γ-
piperazic acids.  Following this new synthetic route, we have prepared N-Alloc-
(S,S)-γ-OTBSPip1 23,  N-Alloc-(R,R)-γ-OTBSPip2 16, and N-Alloc-(R,S)-γ-ClPip 
26. 
During the course or our work towards piperazimycin A it was found that 
the alloc protected versions of the piperazic acids were incompatible with the 
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AMNA diene.  To remedy this problem we decided to prepare Teoc derivatives of 
the piperazic acids 22, 15, and 25, shown in Scheme 6.  Overall yields for the 8 
step synthesis of 27 and 28 averaged 65%, and 29 was obtained in 9 steps and 
22% overall yield. 
 
 
Scheme 6.  Synthesis of N-Teoc-protected, γ-substiuted piperazic acids 27-29. 
 
For the purpose of a model coupling reaction, we also required a bis-Boc 
congener 35 to explore amide coupling conditions en route to a total synthesis of 
1.  To this end, we followed a variation of Danishevsky’s published route, 
Scheme 7 (4-6).  Starting with commercial (R)-lactone 30, opening with 
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methoxide, followed by conversion of the primary hydroxyl to the bromide affords 
31 in 45% yield for the two steps.  TBS protection of the secondary hydroxyl, 
followed by enolate formation and trapping with di-tert-butyl azodicarboxylate 
(DBAD) provides 32, in 56% yield for the two steps.  Deprotonation with NaH and 
cyclization delivers a 1:1 diastereomeric mixture of piperazic esters 33.  Careful 
column chromatography delivers (R,S)-γTBSPip 34 in 40% yield.   Removal of 
the TBS group, application of the Hale protocol (7) to install the γ-chloro 
functionality and hydrolysis provided the target 35 in 45% yield for the three 
steps.   Overall, the 8-step sequence proceeded in 4.6% yield on multi-gram 
scales.    
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Scheme 7.  Synthesis of Bis-Boc-(R,S)-γ-Cl Piperazic Acid. 
 
 
Scheme 8.  Synthesis of AMNA, 40. 
 
With all of the requisite γ-substituted piperazic acids 27-29 and 35 in hand, 
attention now focused on preparing the unnatural AMNA, 40, Scheme 8. 
Beginning with a commercial (S)-allyl glycine derivative 36, Boc protection and 
esterification affords 37 in 96% yield.  Ozonolysis delivers aldehyde 38 in 53% 
yield, and delivers one component for the envisioned Julia-Kocienski olefination 
(11-13) to provide the (E,E)-stereochemistry in AMNA.  The second component 
was derived from commercially available (E)-methyl-4-methylpent-2-enoate 39.   
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Reduction with DIBALH provides, after distillation, allylic alcohol 40 in 75% yield.  
Deprotonation with n-BuLi, conversion to the tosylate and displacement of the 
allylic tosylate with the thiotetrazole and oxidation affords 41 in 53% yield for the 
four steps.  The Julia-Kocienski olefination proceeds by deprotonation of 41 with 
KHMDS in DMF/HMPA to provide an 80:20 mixture of E:Z isomers (11-13).  
Exposure to iodine and UV light isomerizes the diene to >95:5 E:Z.  Deprotection 
of the Boc group with HCl delivers the bench stable AMNA congener, 43 in 70% 
yield for the three steps.  43 was also protected with the Troc group and the ester 
hydrolyzed to afford congener 44.   
For the final component of piperazimycin A we prepared the protected 
forms of (S)-α-MeSerine amino acid 45 for subsequent coupling, Scheme 9.   
Commercial (S)-2-amino-3-hydroxy-2-methylpropanoic acid 45 was Boc 
protected, followed by protection of the primary hydroxyl as a TBDPS ether to 
deliver 46 in 98% for the two steps.  46 was then further elaborated with the HAA 
moiety to provide 47 to complete the northeastern fragment of piperazimycin A 1. 
 
 
Scheme 9.  Synthesis of protected α-MeSer 46, and α-MeSer-HAA 47. 
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With all of the non-proteogenic amino acid components prepared, effort 
focused on construction of key dipeptides en route to a total synthesis of 1.  As 
described by Ma, (14) the peptide couplings were not trivial and each had to be 
optimized independently surveying dozens of coupling reagents, additives, 
solvents and alternative protecting groups on the various amino acid congeners.  
In the recently reported total synthesis of 1 by Ma, (14) they state that they were 
unable to affect the never before described γ-substituted piperazic acid-piperazic 
acid coupling between suitable congeners of 35 and 28.  Thus in their work, they  
   
 
Scheme 10.  Formation of piperazic-piperazic bond utilizing TCFH.   
 
followed the Danishefsky approach, (4-6) coupling acyclic amino acids and then 
cyclizing to form the piperazic acids as shown in Scheme 7.  In our hands, we 
also were unable to couple analogs of 28 and 29; however, protecting groups 
 125 
proved to be the key for this difficult transformation.  The bis-Boc γ-ClPip 35 was 
successfully coupled to 28 in 62% yield employing freshly made 
tetramethylchloroformamidinium hexafluorophosphate (TCFH), to form the acid 
chloride in situ, and provide 48, and the first example of a γ-substituted piperazic 
acid-piperazic acid coupling.  The Boc groups were then removed with TFA and 
subsequent Teoc protection provided 49, however this was in low yield (<12% for 
the two steps).  This provided the southern C5-C14 piperazic acid-piperazic acid 
fragment.   
To construct the eastern half of 1, the Boc group of 47 was 
chemoselectively removed with HCl(g) in EtOAc to deliver 50, (15) which was 
then coupled to 23, under standard HATU coupling conditions to deliver 51 in 
26% yield for the two steps Scheme 11. 
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Scheme 11.  Synthesis of eastern half of piperazimycin A. 
 
In parallel, the Troc-protected AMNA 44 (14) was coupled to 29 under 
TCFH conditions (all others failed entirely) to deliver this dipeptide 52 in 49% 
yield.   Hydrolysis generated 53 in quantitative yield, Scheme 12. 
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Scheme 12.  Synthesis of AMNA, γ-Chloro Piperazic acid dipeptide. 
 
Scheme 13.  Synthesis of northwestern fragment of piperazimycin A.     
 
The northwestern portion of 1 was also prepared, Scheme 13.  γ-OHPip 
27 was coupled to a PMB protected HAA congener 54 to provide 55 in 87% yield.  
Hydrolysis, subsequent HATU-mediated coupling with AMNA congener 56 and a 
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second hydrolysis led to dipeptide 57 in 60% yield for the three steps.  However, 
our most optimal coupling conditions developed in Scheme 10 utilizing freshly 
prepared TCFH proved ineffective to achieve the γ-substituted piperazic-
piperazic bond between 57 and 29, 35 and 51.  
During the course of this work we have synthesized all five of the non-
proteogenic amino acids found in piperazimycin A 1, and synthesized four 
advanced dipeptides (two with the HAA motif attached).  Importantly, we 
achieved the first successful γ-substituted piperazic acid-piperazic acid coupling, 
mediated by TCFH, to synthesize the southern (R,S)-γClPip-(S,S)-γOHPip 
dipeptide 49.  It is unfortunate that our peptide coupling approach ultimately 
failed to produce piperazimycin A, however a new efficient MAOS route was 
developed to produce γ-substituted piperazic acids, and a new peptide coupling 
route was developed utilizing TCFH as a coupling reagent for piperazic acids. 
 By combining our peptide approach toward the synthesis of piperazimycin 
A and the acyclic approach of Ma (14) it may be possible to synthesize 
piperazimycin A in the future, Scheme 14. 
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Scheme 14.  Proposed alternative route towards the synthesis of piperazimycin 
A, 1. 
 
By utilizing advanced intermediate 58, synthesized by Ma, TCFH mediated 
coupling with 51 should produce coupled material 59.  With 59 in hand a zinc 
mediated deprotection of the Troc protecting group will furnish the alcohol which 
can then be cyclized under Mitsunobu conditions to give 60, (14).  After the 
cyclization, removal of the CBz protecting group with Pearlman’s catalyst, 
Pd(OH)2, should give the mono-teoc protected bis-piperazic coupled compound 
61. 
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Scheme 15.  Proposed completion of piperazimycin A, 1. 
 
 Once 61 is completed coupling with 44 utilizing our TCFH methodology 
should provide coupled material 62.  Troc deprotection with zinc and coupling of 
(R,R) piperazic acid with HATU could provide 63.  After successful synthesis of 
63, saponification with K2CO3, cyclization with TCFH, and global deprotection 
with TBAF could be a potential new route to provide the natural product 
piperazimycin A. 
 Another potential reagent that could be useful toward an alternative 
synthesis of piperazimycin A was recently reported by Ley for the total synthesis 
of Chloptosin (16).  To form the piperazic-piperazic bond, Ley utilized the 
Ghosez’ coupling reagent, 1-chloro-N,N-2-trimethyl-1-propenylamine, Figure 4. 
(17). 
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Figure 4.  Structure of Ghosez’ Reagent. 
 
 The Ghosez’ reagent is very similar to TCFH, and may be able to produce 
the γ-substituted piperazic-piperazic bond formation on the fragments of 
Piperazimycin A, 1, where TCFH failed.  With these two alternate route it may be 
possible to complete the total synthesis of Piperazimycin A in the future utilizing a 
peptide-based approach. 
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Piperazimycin Experimental- 
 
(E)-5-(4-methylpent-2-enylthio)-1-phenyl-1H-tetrazole 41: 
To a 500 mL flask containing alcohol 40 (2.45 g, 0.024 mol), under argon, was 
added anhydrous THF (200 mL), and cooled to -78 oC.  n-BuLi (16.8 mL, 0.027 
mol) was added over a 5 min period and allowed to stir at -78 oC for 15 min.  
Solid p-toluene sulfonyl chloride (5.49 g, 0.029 mmol) was added under positive 
argon pressure all at once, and the reaction was stirred for 3 h at -78 oC.  To the 
reaction was added solid sodium thiotetrazole (7.21 g, 0.056 mol) all at once at   
-78 oC, and the reaction was allowed to warm to room temperature overnight.  
Once complete the reaction was added to a separatory funnel containing 250 mL 
H2O, and 250 mL EtOAc, the layers were separated and the product extracted 2x 
with 250 mL EtOAc.  The organic layers were washed with 500 mL brine solution, 
dried with MgSO4, filtered, and concentrated.  The crude material was purified by 
column chromatography with a 1:3 EtOAc:Hexanes to obtain thioether 41 (4.5 g, 
72 % yield).  1H NMR (400 MHz, CDCl3)  7.55 (m, 5H), 5.77 (dd, J = 6.4, 15.2 
Hz, 1H), 5.55 (m, 1H), 3.99 (s, 2H), 2.27 (m, 1H), 0.96 (s, 3H), 0.95 (s, 3H). 13C 
NMR (100 MHz, CDCl3)  144.3, 130.3, 130.0, 124.1, 120.1, 36.1, 31.1, 22.2.  
HRMS (Q-TOF): m/z calc for C13H16N4S [M + H]:  261.1174; found 261.1174. 
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(E)-5-(4-methylpent-2-enylsulfonyl)-1-phenyl-1H-tetrazole 42: 
To a 250 mL flask containing 41 (5.15 g, 0.20 mol), was added EtOH (60 mL), 
and H2O2 (67 mL, 0.594 mol).  To this was added ammonium heptamolybdate 
tetrahydrate (4.89 g, 0.004 mol) and the reaction stirred overnight.  Once 
complete the reaction was diluted with H2O (100 mL), cooled to 0 oC, and slowly 
quenched with sodium thiosulfate until bubbling ceased and the reaction turned 
blue.  The reaction was added to a separatory funnel and extracted 3x 200 mL 
EtOAc.  The organic layer was dried with MgSO4, filtered, and concentrated.  The 
crude material was purified by column chromatography using 1:3 
EtOAc:Hexanes to obtain pure 42 (5.70 g, 98 % yield).  1H NMR (400 MHz, 
CDCl3)  7.62 (m, 5H), 5.92 (dd, J = 6.8, 15.6 Hz, 1H), 5.44 (m, 1H), 4.37 (d, J = 
7.6 Hz, 2H), 2.33 (m, 1H), 0.98 (s, 3H), 0.96 (s, 3H). 13C NMR (100 MHz, CDCl3) 
 151.8, 131.4, 129.6, 125.1, 110.0, 59.8, 31.3, 21.5. HRMS (Q-TOF): m/z calc 
for C13H16N4O2S [M + H]:  293.1072; found 293.1080. 
 
 134 
 
(S,4E,6E)-methyl 2-(tert-butoxycarbonylamino)-8-methylnona-4,6-dienoate 
scheme 8: 
A  250 mL shlenck flask with solid KHMDS (2.46 g, 0.0123 mol) was vacuum 
purged 3x with argon, anhydrous DMF was then added (80 mL), and cooled to    
-78 oC.  A solution of 42 (3.08 g, 0.0105 mol) in anhydrous DMF (20 mL) was 
added over 10 min. and the reaction stirred at -78 oC for 5 min.  A solution of 
aldehyde 38 (2.03 g, 0.0088 mol) in anhydrous DMF (20 mL) was added over 
10min. and the reaction was stirred and allowed to warm to room temperature 
overnight.  Once complete the reaction was quenched with H2O (250 mL) and 
added to a separatory funnel with EtOAc (400 mL).  The layers were separated 
and the water layer extracted 2x 250 mL EtOAc.  The organic layer was then 
washed with 500 mL saturated brine solution, dried with MgSO4, filtered, and 
concentrated.  The crude material was purified by column chromatography using 
1:3 EtOAc:Hexanes to obtain pure 8 (1.83 g, 70 % yield).  To obtain mainly the 
trans diene, the pure material was dissolved in Et2O (100 mL), and a catalytic 
amount of I2 (50 mg) was added, this was then refluxed utilizing UV light 
overnight to furnish the desired material in quantitative yield.  1H NMR (400 MHz, 
CDCl3)  6.21 (m, 2H), 5.70 (m, 2H), 4.37 (m, 1H), 3.72 (s, 3H), 2.71 (m, 1H), 
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2.50 (m, 1H), 2.33 (m, 1H), 1.42 (s, 9H), 1.04 (s, 3H), 1.01 (s, 3H). 13C NMR (100 
MHz, CDCl3)  = 172.3, 154.4, 143.3, 137.2, 129.7, 129.4, 79.4, 54.6, 49.9, 36.0, 
32.2, 28.1, 21.7.  HRMS (Q-TOF): m/z calc for C16H28NO4 [M + H]:  299.2052; 
found 299.2048. 
 
Representative experimental for the synthesis of (3R,5S)-1-
(allooxycarbonyl)-5-chloropiperazine-3-carboxylic acid (N-Alloc-(R,S)-γ-
ClPip) 25: 
 
Weighed 12 (116 mg, 0.724 mmol) into a 5 mL microwave vial and dissolved in 4 
ml pyridine, and cooled to 0 oC.  Slowly added allyl chloroformate (154 L, 1.45 
mmol) via pipette.  The MW vial was then capped and heated to 120 oC for 10 
min.  The reaction was added to an addition funnel with 100 ml sat. NaHCO3 and 
100 ml EtOAc, the layers were separated and extracted with an additional 100 ml 
EtOAc.  The organic layers were washed with 100 ml brine, dried over MgSO4 
and concentrated.  The crude material was purified via silica chromatography 
with EtOAc:Hexanes 1:3 to 1:2 gradient.  The fractions were concentrated to a 
light brown oil to afford pure 14 (130 mg, 74%).  1H-NMR (400 MHz, CDCl3) δ 
5.94 (m, 1H), 5.33 (d, J = 17.2 Hz, 1H), 5.25 (d, J = 10.4 Hz, 1H), 4.65 (d, J = 6.0 
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Hz, 2H), 4.07 (m, 1H), 3.87 (m, 1H), 3.78 (s, 3H), 3.15 (m, 1H), 2.36 (m, 1H), 
1.76 (m, 1H).  13C-NMR (100 MHz, CDCl3) δ = 171.4, 155.4, 132.7, 118.4, 77.5, 
67.1, 64.7, 57.1, 52.8, 51.4.  LC/MS = 1.404.   
 
 
Weighed 14 (50 mg, 0.205 mmol) into a 25 mL r.b. flask, dissolved in 5 mL 1:1 
ACN:CCl4, and cooled to 0 oC.  Triphenylphosphine (81 mg, 0.307 mmol) was 
then added all at once.  The reaction was allowed to reach r.t. and stirred 
overnight.  Once complete the reaction was concentrated in situ and purified via 
column chromatography with EtOAc:Hexanes 1:1.  The fractions were 
concentrated to a clear oil to afford pure 24 (54 mg, 40%).  1H-NMR (400 MHz, 
CDCl3) δ 5.91 (m, 1H), 5.31 (d, J = 17.2 Hz, 1H), 5.21 (d, J = 10.4 Hz, 1H), 4.65 
(d, J = 7.6 Hz, 2H), 4.33 (m, 1H), 4.02 (m, 2H), 3.73 (s, 3H), 3.69 (m, 1H), 2.21 
(m, 2H).  13C-NMR (100 MHz, CDCl3) δ = 171.0, 155.7, 132.6, 118.2, 71.8, 67.0, 
53.8, 52.6, 50.9, 35.8.  LC/MS = 2.431.   
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Weighed 24 (65 mg, 0.247 mmol) into a 5 mL r.b. flask, dissolved in THF, 
and cooled to 0 oC.  Slowly added 140 L of 2M LiOH via pipette and stirred for 
20 min.  The reaction was acidified to pH 3 with 2M HCl, and extracted 2x with 25 
ml EtOAc.  The organic layers were washed with 50 ml brine, dried over MgSO4 
and concentrated to a light yellow oil which needed no purification (55 mg, 90%).  
1H-NMR (400 MHz, CDCl3) δ 5.92 (m, 1H), 5.32 (d, J = 17.2 Hz, 1H), 5.25 (d, J = 
10.4 Hz, 1H), 4.65 (m, 2H), 4.20 (m, 1H), 4.02 (m, 1H), 3.90 (m, 1H), 3.75 (m, 
1H), 2.49 (m, 1H), 2.20 (m, 1H) .  13C-NMR (100 MHz, CDCl3) δ = 173.0, 155.5, 
132.6, 118.9, 77.5, 72.1, 67.6, 52.1, 51.2, 35.3.  LC/MS = 2.106. 
 
 
A flame-dried 50ml flask outfitted with a stirbar was charged with acid 35 
(160 mg, 0.439 mmol), and amine 28 (184 mg, 0.439 mmol) was vacuum purged 
3x with argon.  DCM (10 mL) followed by collidine (175 L, 1.32 mmol) was 
added and the reaction stirred until homogeneous.  Freshly made TCFH (246 
mg, 0.878 mmol) was added all at once and the reaction stirred overnight.  Once 
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determined complete by LC/MS and TLC the reaction was quenched with H2O 
and NaHCO3 and extracted with DCM 3x.  The organic layer was dried with 
MgSO4, filtered and concentrated to afford the crude material which was purified 
by silica gel chromatography (EtOAc:Hex 1:3) to afford pure 48 in 62% yield 
(207mg, 0.272mmol).  1H NMR (400 MHz, CDCl3) δ5.15 (m, 1H), 5 0m, 1H), 4.27 
(m, 1H), 4.10 (m, 2H), 4.00 (m, 1H), 3.67 (s, 3H), 2.92 (m, 1H), 2.50 (m, 1H), 
2.22 (m, 1H), 1.78 (m, 2H), 1.60 (m, 2H), 1.59 (s, 3H), 1.44 (s, 3H), 1.42 (s, 18H), 
1.30 (m, 2H), 1.06 (m, 1H), 0.90 (s, 9H), 0.05 (s, 9H).  13C NMR (100 MHz, 
CDCl3) δ = 170.4, 155.8, 153.2, 81.8, 64.9, 63.5, 51.9, 49.6, 48.8, 34.5, 31.7, 
30.3, 29.7, 28.3, 26.9, 25.7, 25.3, 22.6, 20.7, 18.3, 14.1, -1.6, -5.1.  HRMS (Q-
ToF): m/z calc for C33H61N4O10NaSi2Cl [M + Na] 787.3528, found 787.3512. 
 
 
(3R,5S)-3-methyl 1-(2-(trimethylsilyl)ethyl) 5-chloropiperazine-1,3-
dicarboxylate 29: 
Weighed teoc-protected 14 (1.23 g, 0.004 mol) into a 250 mL r.b. flask, dissolved 
in 50 mL 1:1 ACN:CCl4, and cooled to 0 oC.  Triphenylphosphine (2.12 g, 
0.0.0081 mol) was then added all at once.  The reaction was allowed to reach 
room temperature and stirred overnight.  Once complete the reaction was 
concentrated in situ and purified via column chromatography with 
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EtOAc:Hexanes 1:1.  The fractions were concentrated to a clear oil to afford pure 
29 (0.52 g, 40%).  1H NMR (400 MHz, CDCl3) δ=4.42 (m, 1H), 4.28 (m, 2H), 3.88 
(m, 1H), 3.81 (s, 3H), 3.63 (m, 1H), 3.08 (m, 1H), 2.62 (m, 1H), 1.92 (m, 1H), 
1.07 (m, 2H), 0.06 (s, 9H).  HRMS (Q-ToF): m/z calc for C12H24N2O4ClSi [M + H], 
323.1194; found 323.1192. 
 
 
(S)-2-methoxy-2-oxoethyl 2,2,6,10,10-pentamethyl-8-oxo-3,3-diphenyl-4,9-
dioxa-7-aza-3-silaundecane-6-carboxylate 47: 
To a 250 mL round bottom flask containing 46 (345 mg, 0.754 mmol) and methyl 
glycolate (60 mg, 0.90 mmol) was added a solution of 9:1 DCM:collidine (30 mL).  
Diisopropylcarbodiimide (190 mg, 1.51 mmol) was added all at once and the 
reaction stirred overnight.  Once complete the reaction was quenched with 2M 
citric acid (50 mL) and extracted with 3 x 30 mL DCM.  The organic layer was 
dried with MgSO4, filtered, and concentrated.  The crude material was purified via 
column chromatography using 1:1 EtOAc:Hexanes to obtain pure 47 (380 mg, 95 
% yield).  1H NMR (400 MHz, DMSO-d6) δ=7.62 (m, 4H), 7.44 (m, 6H), 7.34 (br s, 
1H), 4.63 (s, 2H), 3.76 (m, 2H), 3.64 (s, 3H), 1.46 (s, 3H), 1.38 (s, 9H), 1.00 (s, 
9H). 13C NMR (100 MHz, CDCl3) δ = 172.4, 167.7, 154.5, 135.5, 133.0, 129.7, 
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127.7, 79.5, 66.2, 61.1, 52.1, 28.3, 26.7, 20.0, 19.2.  HRMS (Q-ToF): m/z calc for 
C28H39NO7Si [M + H], found. 
 
 
(3S,5S)-2-(trimethylsilyl)ethyl 5-(tert-butyldimethylsilyloxy)-3-((S)-7,11,11-
trimethyl-3,6-dioxo-10,10-diphenyl-2,5,9-trioxa-10-siladodecan-7-
ylcarbamoyl)piperazine-1-carboxylate 51: 
To a 25 mL round bottom flask was added amine 50 (100 mg, 0.215 mmol), acid 
23 (87 mg, 0.215 mmol), HOAt (59 mg, 0.430 mmol), and vacuum purged 3x with 
argon.  The solid material was dissolved in a solution of 9:1 DCM:collidine (3 
mL), and cooled to 0 oC.  Solid HATU (164 mg, 0.43 mmol) was added all at once 
and the reaction allowed to warm to room temperature overnight.  Once complete 
the reaction was concentrated in situ then dissolved in EtOAc (50 mL) and 1N 
HCl (50 mL).  The organic layer was extracted with 2 x 50 mL EtOAc, the 
combined organic layers were washed with saturated sodium bicarbonate (50 
mL) and then saturated brine (50 mL).  The organic layer was dried with MgSO4, 
filtered and concentrated.  The crude material was purified via column 
chromatography using 2:3 EtOAc:Hexanes to afford 51 (60 mg, 34 % yield).  1H 
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NMR (400 MHz, CDCl3) δ=7.60 (m, 4H), 7.41 (m, 6H), 4.20 (m, 2H), 4.11 (m, 
1H), 4.04 (m, 1H), 3.88 (m, 1H), 3.71 (s, 3H), 3.68 (m, 1H), 3.39 (m, 1H), 2.75 
(m, 1H), 2.27 (m, 1H), 1.62 (m, 1H), 1.53 (s, 3H), 1.04 (s, 9H), 0.08 (s, 3H), 0.06 
(s, 3H), 0.03 (s, 9H).  HRMS (Q-ToF): m/z calc for C40H66N3O9Si3 [M + H] 
816.4107; found 816.4101. 
 
 
(3R,5S)-3-methyl 1-(2-(trimethylsilyl)ethyl) 5-chloro-2-((S,4E,6E)-8-methyl-2-
((2,2,2-trichloroethoxy)carbonylamino)nona-4,6-dienoyl)piperazine-1,3-
dicarboxylate 52: 
A 50 mL shlenck flask with amine 29 (130 mg, 0.403 mmol), and acid 44 (144 
mg, 0.403 mmol) was purged 3x with argon. The solid material was dissolved in 
a solution of 9:1 DCM:collidine (5 mL), and cooled to 0 oC.  Solid 
tetramethylchloroformamidinium hexafluorophosphate (452 mg, 1.61 mmol) was 
added all at once and the reaction stirred overnight.  Once complete the reaction 
was quenched with H2O (20 mL) and DCM (20 mL).  The reaction was added to 
a separatory funnel and the organic layer separated.  The water layer was 
extracted with 2 x 20 mL DCM, the combined organic layers were dried with 
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MgSO4, filtered, and concentrated.  The crude material was purified via column 
chromatography with 1:3 EtOAc:Hexanes to afford 52 (130 mg, 49 % yield). 
 
 
(3R,5R)-3-methyl 1-(2-(trimethylsilyl)ethyl) 5-(tert-butyldimethylsilyloxy)-2-
(2-(4-methoxybenzyloxy)acetyl)piperazine-1,3-dicarboxylate 55: 
Weighed amine 27 (250 mg, 0.597 mmol) into 100 mL shlenck flask and and 
vacuum purged 3x with argon.  Dissolved in anhydrous DCM (20 mL) then added 
collidine (217 mg, 1.79 mmol), and 54 (117 mg, 0.597 mmol).  Once dissolved 
solid tetramethylchloroformamidinium hexafluorophosphate (335 mg, 1.19 mmol) 
was added all at once and the reaction was stirred overnight.  Once complete the 
reaction was added to a separatory funnel containing Et2O (150 mL) and H2O 
(150 mL), and extracted 2 x 100 mL Et2O.  The combined organic extracts were 
washed with saturated brine (250 mL), dried with MgSO4, filtered, and 
concentrated.  The crude material was purified via column chromatography using 
1:2 EtOAc:Hexanes to afford pure 55 (311 mg, 87 % yield). 
1H NMR (400 MHz, CDCl3) δ=7.28 (d, J = 8.0 Hz, 2H), 6.86 (d, J = 8.0 Hz, 2H), 
5.37 (br s, 1H), 4.56 (m, 2H), 4.21 (m, 4H), 3.93 (m, 1H), 3.79 (s, 3H), 3.67 (s, 
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2H), 2.85 (m, 1H), 2.36 (m, 1H), 1.01 (m, 2H), 0.87 (s, 9H), 0.84 (s, 3H), 0.06 (s, 
3H), 0.04 (s, 9H). 13C NMR (100 MHz, CDCl3) δ = 171.6, 168.3, 159.7, 157.7, 
130.1, 129.3, 117.9, 72.2, 70.4, 69.3, 67.2, 64.4, 62.0 55.4, 51.8, 37.2, 30.8, 
26.3, 22.5, 1.7, -1.8.  HRMS (Q-ToF): m/z calc for C28H48N2O8NaSi2 [M + Na] 
619.2847; found 619.2850. 
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